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CHAPTER 1 
GENERAL INTRODUCTION
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THE GROWING PROBLEM THAT IS CALLED DIABETES
Diabetes mellitus is a heterogeneous disorder characterized by chronic 
plasma glucose elevations (hyperglycaemia). These elevations are the con-
sequence of insufficient insulin secretion that is either absolute or relative 
to an increase in demand. Insulin is a polypeptide hormone produced by 
beta-cells in the pancreatic islands of Langerhans. Insulin suppresses gluco-
se production and release by the liver, and stimulates the uptake of glucose 
from the circulation into the liver, skeletal muscle, and adipose tissue. This 
results in lower blood glucose levels. In the fasting state, insulin is secreted 
at a low basal rate to suppress hepatic glucose production. In response to 
carbohydrate intake (e.g. in a meal), insulin secretion increases rapidly to 
promote the uptake of glucose in peripheral tissue (figure 1). Consequently, 
plasma glucose excursions remain modest. In patients with diabetes, pan-
creatic beta cells fail to produce enough insulin to maintain euglycaemia, 
leading to chronic hyperglycaemia. 
The number of patients with diabetes has almost quadrupled in the past 30 
years, and is projected to further increase by at least 50% to a total of 642 
million in 2040 (2, 3). A global increase in population, improved life expec-
tancy in patients with diabetes, rise in obesity, better screening methods 
and increased awareness all contribute to the growing number of patients 
(2, 4). In the Netherlands, the current estimated number of patients with 
diabetes is 830.000 (5), and this number is expected to increase further to 
1.3 million in 2025, which then equals 8% of the total population (6). 
Two main forms of diabetes are usually distinguished: type 1 and type 2 
diabetes. Type 1 diabetes is an autoimmune disease in which auto-toxic 
T-lymphocytes cause near-complete destruction of pancreatic beta-cells. 
This leads to absolute insulin deficiency in weeks to months (7). Patients rely 
solely on the administration of exogenous insulin to lower blood glucose 
levels and to prevent life-threatening metabolic derangements. Type 2 dia-
betes is characterized by a combination of insulin resistance and (relative) 
insulin deficiency, the latter resulting from a progressive decline in beta-cell 
function. The insulin resistance in type 2 diabetes is strongly associated 
with obesity, a sedentary lifestyle, but also under genetic control (8, 9). The 
mainstay of treatment is diet, exercise and, when necessary, oral medicati-
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on. Initially, this is sufficient to maintain adequate glucose control. Since the 
beta-cell decline is progressive, insulin therapy is ultimately needed in the 
majority of patients at a later stage (10). 
Chronically elevated glucose levels in diabetes lead to microvascular and 
macrovascular complications (11). Microvascular complications – reti-
nopathy, nephropathy and periperal neuropathy – can lead to blindness, 
renal failure and amputation. Diabetes is the leading cause of preventable 
blindness and the development of end-stage renal disease in many western 
countries (12, 13). The risk of developing macrovascular complications, such 
as myocardial infarction or stroke, is increased 2-5 fold in both patients with 
type 1 or type 2 diabetes (14).  
Figure 1 – 24-hour plasma levels of glucose (solid line) and insulin (dashed line) in healthy 
individuals. The arrows indicates meal ingestion. Adapted from Polonsky et al. Twenty-four-
hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin 
Invest. 1988 Feb;81(2):442-8
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INSULIN TREATMENT
In 1922, a 14-year old boy with type 1 diabetes was the first human being 
successfully treated with insulin. Since then, many advancements have 
been made. For instance, insulin is now produced with recombinant DNA 
techniques rather than being derived from animals. Furthermore, insulin is 
injected subcutaneously rather than intramuscularly, using special insulin 
pen devices with disposable fine needles instead of syringes with re-usa-
ble needles requiring frequent cleaning. Treatment with newly developed 
long-acting and rapid-acting insulin analogues approaches human physio-
logy more closely. Although these advancements have improved the lives 
of people with diabetes, durable glucose control remains suboptimal in the 
vast majority of patients with type 1 diabetes or longstanding (i.e. insu-
lin-requiring) type 2 diabetes(19) . Both hyper- and hypoglycaemic episodes 
remain part of everyday life of these patients.
 The imperfection of regular insulin and modern rapid-acting insulin ana-
logues as prandial insulin contributes greatly to the inability to achieve 
optimal glucose control. Regular human insulin forms hexamers after its 
administration in the subcutaneous area (20). These hexamers degrade to 
dimers and then to monomers, which are subsequently absorbed into the 
circulation. The whole process delays insulin absorption and action by at 
Several studies have shown that complications can largely be prevented 
by using intensive insulin treatment, which aims for near-normal glucose 
levels. In the 1990s, a landmark trial (the so-called Diabetes Control and 
Complications Trial (DCCT)) demonstrated that the onset and progression of 
microvascular complications in patients with type 1 diabetes is reduced by 
approximately 60% in patients assigned intensive treatment, as compared to 
those assigned standard insulin treatment (15), and that the advantage was 
sustained over time (16). Similar findings have been obtained in patients 
with type 2 diabetes (17). At the downside, intensive insulin treatment was 
associated with threefold higher risks of hypoglycemia. Therefore, current 
guidelines recommend strict, near-normal, glycaemic control to prevent 
diabetes-related complications, as long as this can be achieved with a low 
risk of hypoglycaemia (18). 
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least 30 minutes (21). The consequently slow onset and prolonged gluco-
se-lowering action results in hyperglycaemia shortly after the meal and a 
risk of hypoglycaemia later-on (figure 2) (22). By modifying the amino acids 
or their position in the insulin molecule – so called insulin analogues – the 
pharmacokinetic properties of subcutaneously administered insulin change. 
Rapid-acting insulin analogues are more rapidly absorbed, but their action 
profile is still considerably slower than the endogenous insulin’s physiologi-
cal time-action profile (figure 2). Therefore, patients  remain at risk for im-
mediate postprandial hyperglycaemia and late postprandial hypoglycaemia 
(23). In addition, patients dose their insulin before the start of their meal. 
It would be more beneficial for patients to dose their insulin afterwards, 
since such timings would allow them to inject a more accurate dose relative 
to what they have eaten. Additionally, the rate of insulin absorption (and 
insulin action) is inversely related to the dose of (rapid-acting) insulin and 
the level of adiposity, meaning that large insulin doses are absorbed slo-
wer than smaller ones, particularly in the obese (24).  In addition, identical 
insulin doses do not always result in identical pharmacological responses, 
either between subjects or within the same individual at different times. 
Figure 2 – Schematic representation of the differences in plasma concentration of insulin 
levels between endogenously produced and exogenously administered insulin
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There are a number of options to enhance insulin absorption and conse-
quently better control postprandial hyperglycaemia and reduce the risk of 
late postprandial hypoglycaemia.  One approach is the development of a 
faster-acting insulin analogue, by adding nicotinamide and arginine to the 
insulin solution. This resulted in an approximately 20% more rapid insulin 
absorption and onset of insulin action and a similarly more rapid glucose-lo-
wering effect (26). Clinical trials to document added benefits are ongoing. 
Secondly, co-administration of insulin with hyaluronidase transiently dis-
rupts the subcutaneous matrix barrier, which normally inhibits bulk fluid 
flow. This product increases the dispersion of insulin in the subcutaneous 
tissue, hence enhancing its absorption into the circulation (27). When in-
jected before a standardized meal, postprandial glycaemic excursions were 
significantly less when hyaluronidase was added to the insulin (28). A third 
approach are heated patches that locally warm the insulin administration 
site, thereby increasing the local blood flow and consequently enhancing 
the absorption of insulin. A recent study has demonstrated that using these 
patches substantially reduces postprandial glucose excursions after a meal 
tolerance test (29). Although promising, these developments are not yet 
available for patients or need larger clinical trials to determine their side 
effects and additional value in daily clinical care. An intervention that is cur-
rently available for clinical care is jet injection technology with which insulin 
is administered directly across the skin using high air pressure instead of a 
needle. This technology potentially accelerates insulin absorption and is the 
topic of this thesis.
METHODS TO ACCELERATE INSULIN ABSORPTION
This between- and within-subject variability in pharmacological action can 
be as high as 30% and results in unpredictable glucose fluctuations with 
hypoglycaemia and hyperglycaemia (25). As such, there is a need for a more 
rapid absorption of exogenously administered insulin that is preferably less 
variable. 
17Chapter 1 - Introduction
JET INJECTION
Traditionally, insulin is administered subcutaneously by a needle, either by 
syringe, insulin pen or insulin pump. A jet injector is a needle-free alterna-
tive for insulin administration. This technique was first developed after it 
had been reported in the 1920-1930s that working with diesel fuel injectors 
led to accidental oil injection in the hands of car mechanics. The first jet 
injection to be documented in a medical journal was in 1937 and lead to the 
development of a jet injector specially designed for medical purposes (30). 
The main application of jet injection in the early years after its development 
was mass vaccine delivery. 
Figure 3 – Jet injection of protamine insulin in an 11-year old girl with diabetes, the first 
patient treated with a jet injector (1).
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Already in 1947, Hingson and Hughes described how they used a jet injector 
for the administration of insulin to a girl with diabetes (figure 3) (1). From 
1966 onward, the first clinical studies with jet-injected insulin appeared. The 
device has been adapted several times since then; gas-driven and spring-dri-
ven jet injectors have been developed, disposable jet injectors have been 
produced and the device has been made easier to handle (figure 4). 
Figure 4 – Different types of jet injectors. (a) represents the jet injector used in the studies in 
this thesis (InsujetTM), (b) represents the InjexTM 30 and (c) represents the medi-jectorTM.
TECHNICAL ASPECTS OF JET INJECTION
A jet injector device forces the insulin at high speed (>100 m/s) through 
a nozzle with a very fine diameter (76-360 µm, typically around 150 µm), 
much smaller than that of a fine needle. The force necessary for penetration 
is generated with a spring or a gas-driven chamber. The insulin then pe-
netrates the skin and disperses itself in the dermis or subcutaneous tissue 
(figure 5). Insulin can be delivered at variable depths in or below the skin, 
depending on the distance from the nozzle to the skin, skin properties, fluid 
velocity, and nozzle diameter (31). 
The injection volume also affects penetration depth and determines injecti-
on duration, which is generally less than 70 ms (32). When insulin is delive-
red across the skin, it forms a small column that terminates in a (subsection 
of a) spherical or ellipsoid dispersion region, depending on exit power (33). 
Because of insulin backflow after its delivery in the skin, the column dia-
meter is about twice the size of the jet nozzle’s diameter (34). With human 
skin, the velocity and nozzle diameter commonly used in commercially 
available jet injectors are adjusted so that the percentage of fluid delivered 
by jet injection approaches 100% (35). The insulin dispersion region is larger 
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Figure 5 – Insulin dispersion pattern after jet injection (a) and  conventional pen administrati-
on (b)
than after conventional syringe-and-needle administration. The consequent-
ly larger surface area could possibly lead to a more rapid absorption of 
insulin into the circulation (figure 2). 
PHARMACOLOGICAL PROPERTIES
Studies on pharmacologic properties of insulin administration by jet injec-
tion date back to the 1960s (36). In pharmacologic studies, drug properties 
can be described by two parameters: pharmacokinetics refer to absorption, 
distribution, metabolism and excretion of the drug, whereas pharmacody-
namics describe the drug effect. For insulin pharmacology, plasma insulin 
levels reflect pharmacokinetic measurements, whereas plasma glucose 
levels or exogenous glucose requirements to maintain stable glucose levels 
reflect pharmacodynamic measurements. 
The first study on jet-injected insulin administration examined two patients 
with type 1 diabetes and four patients with type 2 diabetes, in whom regu-
larly administered porcine insulin with a jet injector or needle-and-syringe 
resulted in comparable fall in glucose levels (36). However, the small study 
population prohibited statistical analysis, so that firm conclusions about 
(a) (b)
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equality or superiority of one of the devices could not be made. Since then, 
ten additional studies concerning jet injection pharmacology have been 
performed (37-46). Most studies have investigated regular insulin and com-
pared a jet injector to administration by needle and syringe.  All studies had 
a cross-over design, meaning that participants, i.e. patients with type 1 or 2 
diabetes or healthy volunteers, tested the jet injector on one occasion and 
the comparator on the other. Most researchers reported that jet injection 
shortened the time until peak insulin levels by about 20-50%. However, 
most of these trials only included 4-12 participants, making it virtually im-
possible to draw statistically robust conclusions (37-39, 41, 42, 44). Only one 
study investigated a rapid-acting insulin analogue. This study found a more 
than 50% reduction in time until maximum insulin levels, as well as higher 
(albeit non-significant) maximum insulin concentrations, but the findings 
were based on only 4 patients (46). 
Several studies have looked at glucose excursions after regular insulin ad-
ministration by jet injection, and found that the postprandial rise in glucose 
levels in patients with diabetes was better controlled after jet injection than 
after needle-and-syringe administration (37, 39, 41, 44, 45), although this 
only reached statistical significance in one study (44). Two studies looked at 
glucose levels in healthy volunteers and found a non-significant reduction 
of 15-40% in time until maximal glucose lowering effect after jet-injected 
insulin (38, 46). Thus, these studies were unable to demonstrate that acce-
lerated insulin absorption by jet injection translates into advanced insulin 
action. In addition, no studies have been performed with rapid-acting 
insulin analogues (which is standard in contemporary insulin regimens) with 
present-day jet injectors and an insulin pen as a comparator.   
PATIENT EXPERIENCE WITH JET INJECTION
An important feature of an insulin device is the convenience and discomfort 
rate as experienced by patients. Despite considerable technical advances 
in pens and pumps, a substantial number of patients still regard insulin 
injections as painful and inconvenient, and therefore skip or delay insulin 
injections  (47-49). In older studies, patients preferred jet injection over 
needle and syringe administration, due to less perceived pain (36, 37, 40, 
45, 50, 51). Three studies examined pain, user-friendliness and patient 
preference in patients with diabetes who used the jet injector at home for 
several weeks (52-54). Among the patients who finished the studies, patient 
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preference towards the jet injector was highly variable. However, all studies 
showed a high drop-out rate due to technical failure of the jet injector or in-
ability to find the right device settings, resulting in painful injections or brui-
sing/bleeding. Only two observational studies investigated long-term use of 
a jet injector (55, 56). These studies found that most patients regarded pain 
and bruising as very mild and over 70% of patients regarded jet injection as 
better than needle and syringe. Furthermore, almost 60% of patients felt 
that they could control their diabetes better by using a jet injector. Howe-
ver, these results should be interpreted with caution because patients were 
highly selected and needle-and-syringes were used as comparator, instead 
of the more user-friendly and contemporary insulin pen.   
DEVICE COSTS
With ongoing rises in healthcare costs, keeping health care expenditure to 
a minimum becomes increasingly important. Currently, diabetes-related 
health care costs are high (57, 58). Pricewise, the jet injectors currently 
available in the Netherlands (Insujet™) or the UK (Insujet™ and Injex™) 
do not differ much from prefilled pen devices. The annual costs for insulin 
administration (assuming a three-year lifespan of the device), including 
nozzles and the device itself but excluding the insulin, range between €230 
and €265 per year for the Insujet™ and lie around €560 per year for the 
Injex™. The annual costs for a ‘conventional’ insulin injection pen in similar 
conditions range between €180 and €290, which is comparable with that of 
the Insujet™ (59). 
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OUTLINE OF THE THESIS
While high pressure insulin administration has traditionally been positioned 
as an alternative to needle administration, jet injection may also improve 
pharmacokinetics. Previous studies suggest that regular insulin reaches the 
blood stream more rapidly when administered with a jet injector as compa-
red to conventional needle-and-syringe administration. Studies comparing 
contempporary rapid-acting insulin analogues and insulin pens are lacking. 
Therefore, we do not know if jet injection could still offer pharmacologic 
benefits for people with diabetes currently treated with insulin. We hypo-
thesized that using a jet injector for rapid-acting insulin analogue adminis-
tration could further accelerate insulin uptake and action, and lead to better 
glucose control.  
First, we tested in a double-blind randomized controlled trial in healthy 
volunteers whether rapid-acting insulin analogues administered with a jet 
injector were absorbed more rapidly from the subcutaneous tissue than af-
ter conventional administration. We also investigated whether this resulted 
in an earlier insulin appearance in the systemic circulation and a faster onset 
and shorter duration of its subsequent glucose-lowering effect. The results 
of this study are provided in chapter 2. 
Since jet injection is supposed to accelerate insulin absorption, we studied 
in chapter 3 whether jet-injected regular human insulin (which is cheaper) 
has the same time-action profile as that of the rapid-acting analogue insulin 
aspart administered by an insulin pen. 
Patients need reliable insulin administration and insulin action to be able 
to adequately adjust their blood glucose. Thus, a reproducible insulin effect 
is an essential feature for devices which are used on a multiple-daily ba-
sis. Previous research has shown that pharmacologic parameters have an 
intra-individual and inter-individual variability that vary between 10-40% 
when insulin is administered with a common needle and syringe (60). We 
compared the inter- and intra-individual variability after  jet injection and 
conventional insulin pen administration, in a randomized controlled study 
described in chapter 4. The effect variability between the two test days was 
the main outcome of that study. 
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As outlined above, BMI and other body composition-related parameters 
can negatively influence absorption of insulin administered with a need-
le-and-syringe. In chapter 5, we investigated if and to what extent insulin 
absorption after jet injection and insulin pen administration was affected by 
BMI and body composition. 
A more rapid insulin absorption may translate to better postprandial glucose 
control, which is an important contributor to overall glycaemic control, par-
ticularly in patients with moderately to well-regulated diabetes (61). In the 
study described in chapter 6, we therefore tested if jet-injected rapid-acting 
insulin analogues prior to a carbohydrate-rich meal results in better post-
prandial glucose control in patients with diabetes.
Patients with diabetes experience hyperglycaemia on a regular basis. When 
marked, such hyperglycaemia may become symptomatic (e.g. thirst and 
polyuria) or even progress to hazardous metabolic derangements such as di-
abetic ketoacidosis. Rapid correction of marked hyperglycaemia is important 
to prevent these metabolic derangements and to alleviate the symptoms. A 
more rapid insulin absorption may translate into faster correction of marked 
hyperglycaemia. In chapter 7, we tested the hypothesis that the more rapid 
insulin absorption seen after jet injection would translate into faster correc-
tion of marked hyperglycaemia than with conventional pen administration. 
Hyperglycaemia in patients with diabetes is frequently encountered in daily 
practice and often treated by a correctional insulin dose, but to determine 
the appropriate dose proves difficult. In the study described in chapter 7, 
we used a modified algorithm to calculate the insulin dose. The accuracy of 
this formula and some clinical recommendations are discussed in chapter 8. 
   
Finally, in chapter 9, the results are summarized and put into perspective. 
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ABSTRACT
Insulin administered by jet injectors is dispensed over a larger subcutaneous 
area than insulin injected with a syringe, which may facilitate a more rapid 
absorption. This study compared the pharmacologic profile of administrati-
on of insulin aspart by jet injection to that by conventional insulin pen.  
Euglycaemic glucose clamp tests were performed in 18 healthy volunteers 
after subcutaneous administration of 0.2 units/kg body wt of aspart, either 
administered by jet injection or by conventional pen, using a randomized,  
double blind, double-dummy, cross over study design. Pharmacodynamic 
and pharmacokinetic profiles were derived from the glucose infusion rate 
(GIR) needed to maintain euglycaemia and from plasma insulin levels, res-
pectively. 
 
The time to maximal GIR was significantly shorter when insulin was injected 
with the jet injector compared with conventional pen administration (51 6 
3 vs. 105 6 11 min, P<0.0001). The time to peak insulin concentration was 
similarly reduced (31 6 3 vs. 64 6 6 min, P< 0.0001) and peak insulin con-
centrations were increased (108 6 13 vs. 79 6 7 mU/L, P=0.01) when insulin 
was injected by jet injection compared with conventional pen injection. Jet 
injector insulin administration reduced the time to 50% glucose disposal by 
;40 min (P<0.0001). 
There were no differences in maximal GIR, total insulin absorption, or total 
insulin action between the two devices. Administration of insulin aspart 
by jet injection enhances insulin absorption and reduces the duration of 
glucose-lowering action. This profile resembles more closely the pattern of 
endogenous insulin secretion and may help to achieve better meal insulin 
coverage and correction of postprandial glucose excursions.
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INTRODUCTION
Administration of insulin by jet injection is a needle-free alternative to con-
ventional insulin administration with syringes or insulin pens. Jet injectors 
deliver insulin at a high velocity (typically >100 m/s) across the skin in the 
subcutaneous tissue and may dispense the insulin over a larger area than in-
sulin injected with a syringe (1). This may enhance the efficiency with which 
insulin is absorbed from the subcutaneous compartment into the circulation 
so that the insulin peak can be advanced and the duration of (glucose-lowe-
ring) action reduced. Studies on jet injection technology for insulin adminis-
tration date back to the 1960s (2). Most have suggested faster absorption 
of regular and NPH insulin when injected with a jet injector rather than 
with a syringe (3-8). Data on the use of jet injectors for the administration 
of rapid-acting insulin analogues are limited to one open-label study. In that 
study, peak insulin levels were reached in about half the time when lispro 
insulin was injected with a jet injector instead of a syringe. However, the 
glucose-lowering time-action profiles were not significantly different, the 
number of subjects examined was low (n = 4), and the dose of insulin tested 
was relatively high (30 units for all) (9). 
Although rapid-acting insulin analogues have clearly advanced glycaemic 
treatment of type 1 and insulin-requiring type 2 diabetes, their pharmaco-
logical profile is still far from mimicking the profile of endogenous insulin 
release. Indeed, the time until insulin’s maximal glucose lowering effect 
generally amounts to .90 min, and the duration of significant hyperinsuline-
mia often exceeds 3 hours (10-12). As a consequence, risks of (immediate) 
postprandial hyperglycaemia and (late) postprandial hypoglycaemia remain 
relatively high in many patients treated with rapid-acting insulin analogues. 
Faster absorption of insulin may reduce these risks and may provide a more 
physiological meal-time substitution of insulin. The aim of this study was 
therefore to compare the pharmacodynamic and pharmacokinetic profile of 
subcutaneous administration of the rapid-acting insulin analogue aspart by 
jet injection to that of administration by conventional insulin pen in healthy 
individuals using the euglycaemic glucose clamp technique (13). We cho-
se to use an insulin pen as comparator because insulin pens may be more 
accurate than syringes (14) and are currently used by the vast majority of 
insulin-treated patients with diabetes in western Europe (15). 
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RESEARCH DESIGN AND METHODS
Written informed consent was obtained from 18 healthy, nonsmoking sub-
jects (men/women 5/13, mean ± SD age 27.2 ± 6 9.4 years, mean BMI 23.6 
± 2.8 kg/m2, mean fasting plasma glucose level 5.09 ± 0.35 mmol/L) who 
were recruited by advertisement. None of the participants were on chronic 
medication (with the exception of oral contraceptives), reported type 2 dia-
betes among first-degree relatives, or had a history of cardiovascular events. 
A pregnancy test was performed in female subjects at the screening visit 
to exclude pregnancy. The study was approved by the institutional review 
board of the Radboud University Nijmegen Medical Centre (currently known 
as Radboud university medical center).  
EXPERIMENTAL STUDY DESIGN 
All participants underwent two euglycaemic glucose clamp experiments 
(13, 16) to investigate the pharmacokinetics and pharmacodynamics of 
rapid-acting insulin delivered by jet injection or conventional pen injection, 
using a double-blind, double-dummy, randomized cross over study design. 
There was a washout period of at least 1 week between the two clamps, 
whereas female subjects were tested at 4- or 8-week intervals to ensure 
that experiments took place during corresponding periods of the menstrual 
cycle. Participants were admitted to the research unit at 08:30 h after an 
overnight fast and having abstained from smoking, alcohol use, and caffeine 
use for at least 24 h. The experiments were performed in supine position 
in a temperature controlled room (22–24°C). Two catheters were inserted 
intravenously. One catheter was inserted in retrograde fashion in a dorsal 
hand vein for blood sampling. This hand was placed in a heated box, kept 
at 55°C to arterialize venous blood (17, 18). The other catheter was placed 
in an antecubital vein of the contra lateral arm for administration of 20% 
dextrose. After instrumentation, a 30-min equilibration period was included 
before blood was sampled for baseline values of plasma glucose and plasma 
insulin. Subsequently, all participants received both insulin (aspart, Novo 
Nordisk, Bagsvaerd, Denmark) in a dose of 0.2 units/kg body weight and a 
comparable volume of placebo solution (Test Medium PenFill, Novo Nordisk, 
Bagsvaerd, Denmark) simultaneously injected subcutaneously in the abdo-
men. On one occasion, insulin was administered by jet injection (Insujet, 
European Pharma Group bv, Schiphol-Rijk, the Netherlands) and placebo 
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by conventional pen (NovoPen III, Novo Nordisk); on the other occasion, 
insulin was injected by the conventional pen and placebo by the jet injector. 
Two-by-two block randomization was used to randomize the sequence by 
which the two devices were used for insulin and placebo injections. The jet 
injector device used in this study was equipped with a loaded spring mecha-
nism, kept in place by a counter pressure lock/release system. After pressing 
the nozzle perpendicular to the skin, the jet injector releases insulin with 
sufficient force to enter the subcutaneous tissue to a depth equivalent to 
standard needle syringe. To avoid premature insulin release, the system 
unlocks only when sufficient pressure has been applied to the nozzle. Both 
the jet injector and the conventional pen were operated by trained person-
nel only and were prepared by a nurse who was not involved in the trial. 
After administration of insulin and placebo solution, plasma glucose was 
maintained at euglycaemic levels (~5.0 mmol/L) for 8 h by a variable infu-
sion of 20% dextrose, the rate of which was determined by plasma glucose 
measurements at 5-min intervals during the first 4 h and at 10-min intervals 
thereafter. Blood for plasma insulin levels was sampled every 10 min during 
the 1st hour and every 30 min for the remainder of the study. All pharmaco-
dynamic and pharmacokinetic study end points were derived from the exo-
genous glucose infusion rate (GIR) and insulin concentration profiles. The 
primary study end point was the time to maximal GIR (T-GIRmax), corres-
ponding to the time until the maximal glucose-lowering effect of insulin was 
obtained. Secondary pharmacodynamic end points were the maximal GIR 
(C-GIRmax), the time to 50% of glucose disposal (T-GIR50%), and the total 
amount of glucose administered calculated from the area under the curve 
(AUC) (GIRtot). Secondary pharmacokinetic end points included the time to 
maximal insulin concentration (T-INSmax), the maximal insulin concentra-
tion (C-INSmax), the area under the insulin concentration curve (INSAUC), 
and the time until 50% of insulin absorption, calculated as 50% of the area 
under the insulin concentration curve (T-INSAUC50%). 
ANALYTICAL PROCEDURES
Plasma glucose levels were determined in duplicate, immediately after 
blood sampling by the glucose oxidase method (Beckman Glucose Analyzer 
II, Beckman Instruments, Fullerton, CA). Blood sampled for plasma insulin 
measurements was collected in lithium-heparin tubes and placed on ice. Af-
ter centrifugation, the supernatant was stored at 220°C. Plasma insulin was 
measured by radioimmunoassay (19) after all experiments were performed. 
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STATISTICAL ANALYSES 
Assuming a T-GIRmax of 94 min with a SD of 46 min for aspart insulin admi-
nistered subcutaneously in the abdomen by conventional pen injection (10), 
we calculated that a total of 18 subjects would be needed to find a 20% 
reduction in the primary end point with 80% statistical power at the con-
ventional P value of 0.05, after correction for small sample sizes. All data are 
expressed as means 6 SEM, unless otherwise indicated. Mean outcomes for 
all study end points were tested by paired t tests. The GIR and insulin con-
centration profiles were compared by ANOVA. All statistical analyses were 
performed by SPSS 16.0 (Statistical Package for Social Sciences, Chicago, IL). 
A P value of <0.05 was considered statistically significant.
RESULTS
All 18 subjects completed the study. In two subjects, one of the clamp expe-
riments had to be rescheduled because insulin levels failed to increase, with 
both incidents occurring when the  jet injector contained insulin. In one 
instance, the jet injector was incompletely checked for air bubbles in the 
system. In the other instance, the spring was released before proper contact 
could be made with the skin, after which the jet injector was returned to the 
manufacturer and replaced. Injections were well tolerated by the partici-
pants, although some participants regarded the firm pressure required for 
injection with the jet injector as unpleasant. Neither injection mode resul-
ted in skin reactions such as hematomas or redness. Mean plasma glucose 
levels during the clamps were 5.0 ± 0.1 mmol/L with both devices. The 
corresponding coefficients of variation were 8.0 ± 0.8% and 7.3 ± 0.5% for 
the jet injector and conventional insulin pen, respectively. 
PHARMACODYNAMIC END POINTS
All results of pharmacodynamic end points are shown in Fig. 1 and listed 
in Table 1. The time to maximal glucose lowering effect, as represented by 
T-GIRmax, was reduced by >50% when insulin was administered with the 
jet injector as compared with conventional insulin administration. There 
were no differences in maximal glucose-lowering effect (C-GIRmax) or the 
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Figure 1 – Mean GIR after administration of rapid-acting insulin by the jet injector (white 
circles) or the conventional insulin pen (black squares) during the euglycaemic glucose 
clamp
total amount of glucose administered (GIRtot) between the two devices. 
However, the time to 50% of glucose disposal (T-GIR50%), representing the 
total duration of insulin action, was approximately 40 min shorter for insulin 
administration by jet injector than that by conventional insulin pen. 
PHARMACOKINETIC END POINTS 
The results of pharmacokinetic end points are also listed in Table 1. In ana-
logy with the pharmacodynamic results, the time to reach peak insulin le-
vels was reduced by more than 50% after jet injector insulin administration 
as compared with insulin administration with the conventional pen. Insulin 
administered with the jet injector also resulted in higher peak insulin levels 
(C-INSmax) than insulin administered with the conventional insulin pen (Fig. 
2). The INSAUC did not differ between the jet injector and the conventional 
insulin pen, but T-INSAUC50% was significantly shorter for the jet injector, 
indicating faster insulin absorption from the subcutaneous tissue into the 
circulation. 
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Jet Injector 
 
Conventional 
pen
P-value
Pharmacokinetic  
parameters
   T-INSmax (min) 31 ± 3 64 ± 6 <0.0001
   C-INSmax (mU/L) 108 ± 13 79 ± 7 0.012
   INSAUC (unit∙min-1∙ml-1) 14.6 ± 1.6 15.2 ± 1.4 0.53
   T-INSAUC50% (min) 111 ± 5 147 ± 5 <0.0001
Pharmacodynamic  
parameters
   T-GIRmax (min) 51 ± 3 105 ± 11 0.0001
   C-GIRmax (mg∙kg-1∙min-1) 6.49 ± 0.58 6.09 ± 0.56 0.50
   GIRtot (g) 70.0 ± 6.9 83.3 ± 9.8 0.19
    T-GIR50% (min) 123 ± 7 166 ± 6 <0.0001
Table 1 – Pharmacokinetic and pharmacodynamic parameters for insulin administration 
with the jet injector and the conventional insulin pen
Figure 2 – Mean plasma insulin levels after administration of rapid-acting insulin by the 
jet injector (closed symbols, black line) or the conventional insulin pen (open symbols, 
dashed line) during the euglycaemic glucose clamp
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CONCLUSION
In this study, the pharmacodynamic and pharmacokinetic profiles of the 
rapid-acting insulin analogue aspart, injected by either jet injection techni-
que or by conventional insulin pen, were compared. We found that the jet 
injector greatly enhanced the rate of insulin absorption, resulting in a truly 
immediate onset of action and approximately halving of the time to reach 
maximal glucose-lowering effect in comparison with conventional insulin 
administration. In addition, insulin administration by jet injection reduced 
the total duration of hyperinsulinemia and insulin action by 30–40 min 
when compared with conventional insulin administration. There were no 
indications that these benefits of the jet injector over the conventional pen 
differed between women and men. 
Our data are in line with previous studies that have shown a more rapid 
increase in insulin levels and shorter duration of hyperinsulinemia after ad-
ministration of regular insulin by jet injection compared with administration 
by needle syringe (3-8). The results of the current study also extend those of 
a recent study performed by Sarno et al. (9), who compared administration 
of various insulins (including lispro insulin) with jet injection to that with 
needle syringes. In that study, time to peak insulin levels after lispro insu-
lin administration was shorter for the jet injector than for needle syringe 
injection, but a statistically significant pharmacodynamic effect could not be 
established. Also, the number of volunteers examined was small (n = 4) and 
the dose of insulin used was fixed at a relatively high level (30 units for all). 
Our study convincingly shows the pharmacokinetic and pharmacodynamic 
superiority of jet injection over conventional needle pens for administration 
of rapid-acting insulin at a dose that is realistic for many people with type 1 
or type 2 diabetes. It is also the first time that jet injection technology was 
compared with an insulin pen, which most patients prefer over syringes for 
There was no indication that sex modified the pharmacodynamic or phar-
macokinetic differences between the jet injector and conventional pen for 
insulin administration. In fact, the jet injector performed significantly better 
than the conventional pen in both groups, when analyzed separately (data 
not shown but available upon request).
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their ease of use and high level of accuracy (20). 
Insulin injected by jet injection displays a specific cone-like dispersion pat-
tern in the subcutaneous tissue with a relatively large surface area(1, 2). It 
seems plausible that this dispersion pattern enhances absorption of insulin 
into the circulation, thus explaining a more immediate glucose-lowering 
effect. The current jet injector uses a high-velocity jet that ensures .90% 
delivery of injected insulin into the subcutaneous tissue, without risking pe-
netration of the underlying muscle, at a jet stream diameter of ~0.15 mm. 
These device characteristics compare favorably to the length and diameter 
of pen needles that typically measure 6–8 mm and 0.5 mm, respectively. 
A limitation to the use of jet injectors in comparison with insulin pens is 
that sufficient training is required with both air-free filling of the injection 
chamber and the injection procedure itself. We had to reschedule the first 
experiment, probably because of an air bubble in the system, and another 
experiment because of early discharge of the spring system, possibly related 
to failure of the lock/release system. However, after proper training, admi-
nistration of the entire dose of insulin can be achieved in almost all instan-
ces (21).
The pharmacokinetic and pharmacodynamic profile of rapid-acting insulin 
administered by the jet injector approached the physiological pattern of 
endogenous insulin secretion and subsequent glucose-lowering response 
more closely than insulin administered by a conventional insulin pen. 
Consequently, a more physiological meal insulin substitution may decrease 
immediate postprandial hyperglycaemia, whereas the more rapid tapering 
of hyperinsulinemia may reduce the risk of late postprandial hypoglycaemia. 
Faster insulin action may also advance correction of erratic hyperglycaemia. 
These effects are clinically relevant for patients aiming for strict glycae-
mic control. However, postprandial glucose may contribute less to overall 
glycaemic control than pre-prandial glucose in patients with diabetes, and 
the role of postprandial hyperglycaemia as an independent cardiovascular 
risk factor is still uncertain (22). Therefore, appropriately designed studies 
are needed to determine whether and to what extent the favorable phar-
macological properties of insulin administration by jet injection found in 
this study translate into clinical benefit in the longer term for patients with 
diabetes. 
A strength of our study is the use of a double-dummy cross over study 
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design, ensuring that both participants and investigators were truly blin-
ded during the execution of the experiments. This contrasts with previous 
studies on jet injectors. Moreover, because we used a placebo solution that 
contained the same ingredients as the insulin solution (except for insulin), 
the smell and viscosity of the two liquids were indistinguishable. A limitati-
on of this study is that the euglycaemic clamps were performed in healthy 
individuals rather than in patients with diabetes, the target population for 
such a device. In addition, only one insulin dose was investigated; it cannot 
be determined with certainty whether the current differences in time-ac-
tion profiles can be extrapolated to other insulin doses. Finally, the ease of 
use of the jet injector was not tested, which is important for a device that is 
aimed at being used on a daily basis. 
In conclusion, the current study shows that when insulin is administered 
with a jet injector instead of a conventional insulin pen, a more rapid onset 
of insulin action can be achieved. Insulin administered by the jet injector re-
sembles the pattern of endogenous insulin secretion more closely and could 
therefore be useful in providing a more physiologic postprandial insulin pro-
file. Future research will need to investigate whether these results can be 
replicated in patients with diabetes and what the clinical implications are.
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ABSTRACT
Rapid-acting insulin analogues are generally preferred over regular hu-
man insulin because of their more immediate onset of action and shorter 
time-action profile. However, these analogues are expensive and in large 
parts of the world unavailable for people with insulin-requiring diabetes. Jet 
injection has been demonstrated to facilitate faster insulin absorption. We 
determined whether administration of regular human insulin by jet injecti-
on achieves the same pharmacological properties as that of a rapid-acting 
insulin analogue. 
Twenty healthy volunteers received  regular human insulin (0.2 units/kg) 
by jet injection. Glucose20% was infused intravenously  to maintain eugly-
caemia over six hours. The glucose infusion rates (GIR) were determined to 
compare pharmacological profiles. These profiles were compared with data 
from two other studies in which a similar dose of insulin aspart was admi-
nistered by conventional pen.
Regular human insulin by jet injection had a faster onset of glucose-lowe-
ring effect compared to aspart by conventional pen (T-GIR50%, 30.8±2.9 
versus 43.1±3.2 minutes, P<0.01). There were no differences in time to 
maximal GIR (106.1±11.9 versus 95.8±9.2 minutes, P =0.50), maximal GIR 
(8.6±0.7 versus 7.7±0.7 mg/kg/min, P =0.0.33), total glucose-lowering effect 
(101.0±9.8 versus 87.6±7.0 g, P =0.28), and time until 50% of glucose dispo-
sal (144.8±5.6 versus 151.3±5.1 minutes, P =0.39). 
Jet-injected regular human insulin had a pharmacological profile that was 
essentially not dissimilar from that of aspart insulin, and can therefore be 
used as an alternative for conventionally administered rapid-acting insulin 
analogues. 
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INTRODUCTION
Rapid-acting insulin analogues have largely replaced regular human insulin 
as the first-choice prandial insulin in basal-bolus insulin regimens for the tre-
atment of type 1 and insulin-requiring type 2 diabetes, at least in the Wes-
tern world (1). The clinical benefits of rapid-acting insulin analogues stem 
largely from their more rapid absorption into the circulation. These include 
faster onset and shorter duration of glucose lowering action, alleviation of 
the need for 30-minute intervals between insulin administration and meals, 
better postprandial glucose control and reduced risks of hypoglycaemia 
(2). However, many patients with diabetes remain devoid of these benefits 
when regular human insulin is the only affordable prandial insulin available, 
which is the case in many low- or middle income countries (3), or when 
insurance companies refuse to (fully) reimburse rapid-acting analogues (4). 
Finally, although true allergy is rare, local skin reactions to insulin analogues 
have been described (5).
Administration of insulin by jet injection is a needle-free alternative to 
conventional administration by insulin pen or syringes. A jet injector deli-
vers insulin at high velocity directly across the skin, enabling a more rapid 
uptake than that of conventionally administered insulin. We and others have 
shown that jet injection advances the absorption of insulin and its subse-
quent glucose-lowering effect by 40-50%, when compared to conventionally 
administered insulin (6-11). The advancement in insulin action appears 
similar to what can be achieved by switching from regular human insulin to 
a rapid-acting insulin analogue. We therefore aimed to test the hypothesis 
that regular human insulin, administered by jet injection, has a similar phar-
macological profile as that of a rapid-acting insulin analogue administered 
by conventional pen.
RESEARCH DESIGN AND METHODS
PARTICIPANTS
This study enrolled 40 non-smoking, non-pregnant, healthy adults with a 
BMI between 18- 32 kg/m2.  Twenty of these were newly recruited and 
matched according to age, sex, and body weight to 20 participants who-
se data from similarly performed  studies on the pharmacology of aspart 
insulin by conventional pen (executed according to the same protocol  in 
our research center in 2010 and 2015) were used for comparison (7, 11). 
Exclusion criteria were equal to those published earlier (7, 11). The study 
was approved by the institutional review board of the Radboud university 
medical center and performed according to the declaration of Helsinki and 
Good Clinical Practice. All participants provided written informed consent.
EXPERIMENTAL STUDY DESIGN
All participants underwent a euglycaemic glucose clamp in supine position 
in a temperature-controlled room (22–24°C), as described elsewhere (7, 11). 
Briefly, two intravenous catheters were inserted, one with the hand placed 
in a heated box to arterialize venous blood for frequent blood sampling, 
and the other for the administration of glucose. After obtaining baseline 
variables, regular human insulin (Humulin R, Eli Lilly and Company, Indiana-
polis, USA) by jet stream (Insujet, European Pharma Group bv, Schiphol-Rijk, 
the Netherlands) or insulin aspart (Novo Nordisk, Bagsvaerd, Denmark) by 
conventional pen (NovoPen III or IV, Novo Nordisk, Bagsvaerd, Denmark) 
was administered subcutaneously in the abdomen in a dose of 0.2U per kg 
of body weight. Blood was sampled at 5-min intervals during the first three 
hours and at 10-min intervals for the following three hours of the study for 
immediate measurement of plasma glucose levels. Intravenous glucose 20% 
solution was administered as needed to maintain the target plasma glucose 
level of 5.0 mmol/l. 
All pharmacological variables were derived from the body-weight standardi-
zed glucose infusion rates (GIR) (7, 11). Primary outcome was the time until 
maximal glucose lowering effect, as determined from the GIR curve (T-GIR-
max). Secondary endpoints included the maximal GIR (GIRmax), time to 
50% of maximal GIR (T-GIR50%),  the total amount of glucose given (Glucto-
tal), the area under the GIR-curve after the first and second hour (AUC-GIR-
1hour and AUC-GIR2hours)and the time of 50% of glucose disposal, i.e. the 
median of the GIR profile (T-GIRAUC50%). 
STATISTICAL ANALYSES
All data are expressed as means ± SEM, unless otherwise indicated. In accor-
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dance with the European guideline on biosimilar insulins, the equivalence 
threshold was set at a two-sided 10% difference in T-GIRmax and establis-
hed when the 95% CIs for the ratio of means were within this range (12). If 
equality could not be established, mean outcomes were tested for normal 
distribution and compared with unpaired T-tests or Mann-Whitney U tests 
accordingly, to test for superiority of one of the treatment modalities. The 
GIR-profiles were analyzed using a two-way repeated measures ANOVA with 
the device as between-subject factor. A P-value of <0.05 was considered sta-
tistically significant. All statistical analyses were performed using SPSS (IBM 
SPSS Statistics for Windows, Version 20.0, IBM Corp, Armonk, NY).
RESULTS
In total, 22 persons were screened and 20 were included in the final analy-
ses and subsequently matched to 20 participants from the previous stu-
dies mentioned above (7, 11). One participant could not participate due 
to anemia, and one participant withdrew consent due to lack of time. The 
two groups were well matched for age (22.5 ± 0.6 years versus 22.5 ± 0.8 
years, for jet versus conventional injection, respectively), sex (3 males in 
both groups) and BMI (21.8 ± 0.4 kg/m2 versus 22.0 ± 0.5 kg/m2) (table 1). 
Plasma glucose values during the clamps were 5.1±0.01 mmol/l (coefficient 
of variation (CV) 6.5±0.6%) for jet-injected regular human insulin versus 
5.1±0.02 mmol/l (CV 7.0±0.4%) for the experiments with IA (P=0.51). 
Regular human insulin by 
jet injection
Insulin aspart by conventi-
onal pen
Male:Female 3:17 3:17
Age, years 22.0 (18-29) 21.0 (19-33)
Weight, kg 63.4 ± 1.7 63.5 ± 1.9
BMI, kg/m2 21.8 ± 0.4 22.0 ± 0.5
Insulin dose, IU 13.0 (9-17) 12.0 (10-16)
Table 1 - Baseline characteristics. Data are expressed as number, median and range or mean 
± SEM.
The time-action profiles for the GIR were similar for jet-injected regular 
human insulin and for conventionally administered insulin aspart (PANO-
VA=0.29,  figure 1), except that jet-injected regular human insulin had a 
slightly earlier onset of action, as reflected by 10-15 min shorter T-GIR50%. 
Furthermore, the glucose-lowering effect of jet-injected regular human 
insulin during the first hour was larger as well (table 2). The two interven-
tions did not significantly differ with respect to other pharmacodynamic 
endpoints, including the time until maximal glucose-lowering effect, the 
maximal glucose lowering effect, the time until 50% of the glucose lowering 
effect and the total glucose-lowering effect (table 2). 
Regular hu-
man insulin 
by jet
Insulin as-
part by pen
P-value Ratio (95% CI)
T-GIR50%, min 30.5 ± 2.9 43.1 ± 2.8 0.004 0.71 (0.55-0.89)
T-GIRmax, min 106.1 ± 11.9 95.8 ± 9.2 0.50 1.11 (0.81-1.49)
GIRmax, mg/kg/
min
8.6 ± 0.7 7.7 ± 0.7 0.33 1.12 (0.87-1.44)
Gluctotal, g 101.0 ± 9.8 87.6 ± 7.0 0.28 1.15 (0.89-1.48)
T-GIRAUC50%, 
min
144.8 ± 5.6 151.3 ± 5.1 0.39 0.96 (0.86-1.06)
AUC-GIR1hour, g 15.7 ± 1.3 10.4 ± 1.2 0.004 1.51 (1.14-2.05)
AUC-GIR2hour, g 40.2 ± 3.6 34.3 ± 3.3 0.219 1.17 (0.90-1.54)
Table 2 - Pharmacodynamic outcome variables. The P-value was calculated for superiority. 
The ratio with 95% CI was calculated for equivalence.
CONCLUSION
This study shows that the pharmacodynamic profiles of jet-injected regular 
human insulin and conventionally administered aspart insulin are largely 
superimposable. There were no differences with respect to the maximal 
glucose lowering effect, time to maximal glucose lowering effect or total 
glucose-lowering effect. Remarkably, the onset of the glucose-lowering ac-
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tion was somewhat quicker with the jet injector than with the conventional 
pen, despite the use of ‘slower’ regular human insulin in the jet injector and 
‘faster’ insulin aspart in the conventional pen. 
Action of regular human insulin after jet injection was faster than what has 
previously been reported. In studies dating back to the 1980s, the time to 
maximal glucose-lowering effect ranged from 130 to 170 minutes when 
regular human insulin was injected by jet injection (13, 14). However, these 
studies were performed in a small number of subjects with different types 
of jet injectors, which makes comparison with our study difficult. 
Our findings may have important clinical consequences. Since the phar-
macodynamic profiles of the two treatments investigated here were about 
similar, it is likely that the potential clinical benefits of rapid-acting insulin 
analogues are also applicable to regular human insulin when injected by 
jet stream. For example, the faster onset of action, even exceeding that of 
the rapid-acting insulin analogue, would obviate the need for a 30-minute 
interval between insulin administration and eating a meal. 
Figure 1 - Glucose infusion rate after human insulin administration by jet injection (◦) and 
insulin aspart by conventional pen administration (▪).
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Our studies were not designed to investigate cost-effectiveness. However, 
given that the price of the current jet injector and its disposables  is in the 
range of that of conventional insulin pens and human insulin is up to 20% 
cheaper than insulin analogues, using a jet injector for human insulin may 
be a more affordable option than using rapid-acting insulin analogues  (15, 
16). 
Our study has limitations that warrant discussing. First, the study was not 
designed to formally prove equivalence.  However, the clinical significance 
of the small numerical differences are unlikely to become clinically relevant, 
considering that the confidence intervals fall within the expected variabi-
lity of the pharmacological effects of both insulin products (17). Another 
limitation concerns the recruitment of healthy subjects instead of patients 
with diabetes. However, we expect that the results can be extrapolated to 
patients with diabetes, since earlier studies, including our own, showed that 
the pharmacological benefit of jet injectors for the administration of insulin 
were about similar for people with or without diabetes (6-8). Finally, the 
probes of the in-house radio-immuno-assay that we normally use appea-
red to have different affinities for regular human insulin and insulin analo-
gues, so that the pharmacokinetics of the two types of insulin could not be 
compared. On the other hand, the clinical relevance of pharmacokinetic 
outcomes is of limited importance given the comparable pharmacodynamic 
profile
In conclusion, using a jet injector for the administration of regular human 
insulin advances its pharmacological profile to that of a rapid-acting insulin 
analogue administered by conventional methods. Therefore, jet-injected 
regular human insulin could have the same clinical benefits of a rapid-acting 
insulin analogue, presumably at lower costs. Further studies are necessary 
to demonstrate whether the improved pharmacological profile of jet-injec-
ted human insulin equally benefits long-term metabolic control with less 
glucose fluctuations, lower risk of hypoglycaemia and improved quality of 
life. 
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ABSTRACT
Jet injection has been shown to advance the absorption and action of 
rapid-acting insulin. In this study, we compared  the variability of this effect 
between jet injection and conventional  administration of the rapid-acting 
insulin analogue aspart.
30 healthy volunteers were enrolled in this randomized controlled blinded 
parallel study. On two test days, performed within one week, they recei-
ved insulin aspart (0.2 units/kg body weight ), either by jet injection or by 
conventional pen, followed by a 6-hour euglycaemic glucose clamp. Plasma 
glucose and insulin levels and glucose infusion rates were measured every 
5 to 10 minutes to calculate pharmacologic endpoints and the variability in 
these endpoints. 
Jet injection advanced the times until peak insulin concentrations (T-IN-
Smax) and maximal glucose infusion rate (T-GIRmax) by ~40% (P<0.01). The 
difference between the two test days for these endpoints did not differ 
between jet injection and conventional administration (T-INSmax: 7.3±1.9 
versus 22.3 ± 6.3 min, P=0.074; T-GIRmax: 24.0±3.5 versus 27.3±6.6 min, 
P=0.66).  The corresponding intra-individual coefficients of variation for 
injection by jet or conventional pen were 15.3±3.3 and 22.0±4.6 % (P=0.25, 
Pvariance=0.044) for T-INSmax and 34.5±5.1 and 21.2±4.6% for T-GIRmax 
(P=0.064,  Pvariance=0.62). The variance in maximal insulin concentration 
was significantly less after conventional administration (P=0.039). 
Using a jet injector for insulin administration was associated with slightly 
altered variability in pharmacokinetic endpoints, but with about similar 
variability in pharmacodynamic endpoints compared to conventional admi-
nistration. Variability in these endpoints remains considerable, regardless of 
the method of insulin administration.
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INTRODUCTION
Jet injection provides a needle-free alternative to conventional subcutane-
ous administration of insulin. The jet injector administers insulin at a high 
velocity (typically >100m/s) directly across the skin into the subcutaneous 
tissue, where it is dispersed in a spray-like pattern which facilitates its upta-
ke into the circulation (1). We have previously shown, both in healthy volun-
teers and in patients with diabetes, that insulin absorption from the sub-
cutaneous tissue is considerably enhanced when insulin is administered by a 
jet injector instead of a conventional pen (2, 3). This enhancement leads to 
a 40-50% advancement in the time to reach the maximal glucose-lowering 
effect (2), a shorter duration of insulin action (3), and a faster correction of 
incidental marked hyperglycaemia (4). 
For such an improved insulin effect to become clinically relevant, it needs 
to be reproducible. Large day-to-day variability in insulin effect hampers 
the achievement of optimal glycaemic control (5, 6) and is associated with 
a diminished health-related quality of life, at least in patients with type 2 
diabetes (7). Variability in glucose-lowering effect can be explained by many 
parameters (6), but is in part determined by variability in the absorption of 
insulin from the subcutaneous area into the circulation. Prior studies have 
shown that the intra-individual variability of the metabolic effect of regular 
human insulin and of rapid-acting insulin analogues is still considerable, 
varying between 10-30%, when administered by needle and syringe (8).
 
Studies published in the 1980s suggested about similar intra-individual 
variability for regular human insulin when injected by jet stream as compa-
red to administration by needle and syringe (9, 10). There are no data on 
the intra-individual variability of the pharmacology of rapid-acting insulin 
analogues, when administered by jet injection. Also, previous jet injectors 
were criticized because they were cumbersome to handle and had a high 
propensity for errors, including ‘wet injections’ (1). The current jet injector 
(i.e. Insujet™) has been technically improved to assure better performance 
and easier handling by patients. The aim of this study was to examine the 
variability of the pharmacologic effect of the rapid-acting insulin analogue, 
aspart, when administered by jet injection as compared to that by a conven-
tional pen. 
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RESEARCH DESIGN AND METHODS
PARTICIPANTS
Written informed consent was obtained from 30 healthy volunteers, who 
were recruited by advertisements via websites.  All patients were at least 
18 years of age and had a body-mass index between 18-32 kg/m2. Patients 
were excluded if they had had a major vascular event (e.g. myocardial 
infarction, stroke, symptomatic peripheral artery disease, coronary bypass 
surgery, percutaneous coronary or peripheral artery angioplasty) in the 
previous 6 months, used medication other than oral contraceptives or had 
a medical condition that interfered with the study protocol. Pregnancy was 
excluded where appropriate. The study was approved by the institutional 
review board of the Radboud university medical center (identification code 
2014-1346) and conducted according to Good Clinical Practice and the 
Helsinki Declaration. The study was registered with Clinicaltrials.gov under 
NCT02272296.
EXPERIMENTAL STUDY DESIGN
Fifteen participants were randomized to the jet injector study arm and the 
other 15 participants to the conventional pen study arm, in blinded fashion 
and using a double-dummy design (2, 3). All participants were examined 
on two study days, separated by a maximum of 7 days, during which they 
underwent a 6-hour euglycaemic glucose clamp, as described previously (2). 
Briefly, all experiments were conducted in a temperature-controlled room 
(22–24°C), with the subjects in fasting condition and having abstained from 
smoking, alcohol use and caffeine use for at least 24 hours. After partici-
pants arrived at the research facility, two peripheral catheters were inserted 
intravenously. The hand from which blood samples were drawn was placed 
in a heated box at 55°C to arterialize venous blood (11).  After obtaining 
baseline variables, insulin aspart (Novo Nordisk, Bagsvaerd, Denmark) was 
administered in a dose of 0.2U per kg of body weight by either jet injection 
(Insujet, European Pharma Group bv, Schiphol-Rijk, the Netherlands) or by 
conventional pen with a 31G, 6mm needle (NovoPen IV, Novo Nordisk, Bags-
vaerd, Denmark). The alternate device was used as placebo to administer 
an “empty” injection, i.e. the device looked and felt like it delivered insulin 
but it contained no solution. All injections were given in the lower half of 
the abdomen by an independent research nurse. Both investigators and 
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patients were blinded to which device contained the insulin. Randomisation 
was done by a computer program with the use of blocks of two subjects.
After insulin administration, glucose 20% was infused and glucose infusion 
rate (GIR) was adjusted to maintain euglycaemia, based on plasma glucose 
levels, measured at the bedside at 5-min intervals during the first three 
hours of the study and at 10-min intervals for the following three hours. 
Blood for plasma insulin levels was sampled every 5 minutes during the first 
hour, every 15 minutes for the second hour, and  every 30 minutes thereaf-
ter. 
ANALYTICAL PROCEDURES
Plasma glucose was measured by the glucose enzymatic-amperometric 
method (Biosen C-line GP+, EKF-diagnostic GmbH, Barleben, Germany). 
Blood sampled for determination of plasma insulin levels was collected in 
lithium-heparin tubes. After centrifugation, the supernatant was stored at 
-80°C. Plasma insulin was measured by radioimmunoassay (RIA) (11).
CALCULATIONS AND STATISTICAL ANALYSES
The pharmacokinetic parameters were derived from plasma insulin levels 
and consisted of the time to maximal insulin concentration (T-INSmax), 
the maximal insulin concentration (C-INSmax), the area under the insulin 
concentration curve (AUCINS) and the time until 50% of insulin absorption 
(T-INSAUC50%). For these parameters, we calculated the variance (i.e. stan-
dard deviation squared), inter-and intra-individual coefficient of variation 
(CV)(12) and mean day-to-day difference . The pharmacodynamic para-
meters were derived from the body-weight standardized GIR-curves (the 
amount of glucose infused in mg per kg of body weight per minute)  and 
included variance, inter-and intra-individual CV and mean difference in the 
time until maximal GIR (T-GIRmax), reflecting the maximal glucose lowering 
effect, the maximal GIR (GIRmax),  the area under the GIR curve (AUCGIR), 
and the time until 50% of glucose disposal (T-GIRAUC50%), as described 
previously (2). The variance in T-GIRmax was the primary endpoint. Mean 
outcomes measuring variance endpoints were log-transformed and tested 
using a one-way ANOVA with the device as between-subject factor. Other 
endpoints were tested for normal distribution and compared with an inde-
pendent samples T-test or Mann-Whitney-U test, as appropriate. All statis-
tical analyses were performed using SPSS (IBM SPSS Statistics for Windows, 
Version 20.0, IBM Corp, Armonk, NY). All data are expressed as means ± 
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SEM, unless otherwise indicated, and a P-value of <0.05 was considered 
statistically significant.
RESULTS
Table 1 summarizes the baseline characteristics of the participants. We 
screened and included 33 subjects. Replacements were required for two 
subjects who dropped out due to lack of time before the first experimental 
day, and for one participant for whom rescheduling the second test day 
(because of a technical problem with the Biosen glucose analyzer) proved 
impossible . The subjects were well matched for sex, age, BMI and fasting 
glucose and insulin levels.
GLUCOSE CLAMP 
Baseline glucose values did not differ between the 2 groups (table 1). Plas-
ma glucose values during the glucose clamps were comparable on all test 
days (5.12 ± 0.03 and 5.12 ± 0.03 mmol/l for jet injection versus 5.11 ± 0.03 
and 5.11 ± 0.02 mmol/l for conventional pen, P=0.99). The CVs for glucose 
levels also showed no difference between the two groups (7.15 ± 0.54% and 
7.67 ± 0.61 % for jet injection versus 6.54 ± 0.40% and 6.49 ± 0.45% for the 
conventional pen, P=0.31).
Jet injection Conventional ad-
ministration
Number of patients 15 15
Male : Female 4 : 11 4 : 11
Age, years 21.3 ± 2.1 21.5 ± 2.2
BMI, kg/m2 21.6 ± 2.2 22.0 ± 2.2
Insulin dose, units 13.0 (10-17) 12.0 (11-19)
Fasting plasma glucose, mmol/l 5.4  ± 0.38 5.3  ± 0.23
Fasting plasma insulin, mU/l 10.0 ± 2.5 10.3 ± 2.8
Table 1 - Baseline characteristics. Data are presented as mean ± SD, median and range, or 
number
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PHARMACOKINETIC ENDPOINTS
After jet injection, insulin levels rose more rapidly and to higher levels as 
compared to conventional administration (P<0.001 for both endpoints, 
table 2,). The average time difference for T-INSmax between the two test 
days tended to be smaller for the jet injector (7.3±1.9 versus 22.3 ± 6.3 min, 
P=0.074) and the variance in T-INSmax was less after jet injection (P=0.044). 
However, conventional pen administration was associated with smaller 
differences (P=0.021) and variance (P=0.039) in peak insulin concentrations 
between the two test days ( table 2). The intra-individual differences and 
variances for the other pharmacokinetic parameters did not differ between 
the two devices (table 2 and 3, supplemental figure 1). The inter- and in-
tra-individual CVs were largely comparable for both devices, except for the 
inter-individual CV of T-INSmax, which seemed less after jet injection (table 
3). 
PHARMACODYNAMIC ENDPOINTS
On both test days, the T-GIRmax was reached approximately 40% faster 
when insulin was administered by jet injection than when this was done 
by conventional pen (P≤0.001 for both test days, table 2). The mean in-
tra-individual time differences in T-GIRmax between the two test days were 
24.0±3.5 and 27.3±6.6 min for jet injection and conventional administration, 
respectively (P=0.66, supplemental figure 2). The variance of this endpoint 
was about similar (P=0.59) and the intra-individual CV tended to be slightly 
higher for jet injection than  for conventional administration (P=0.064,  table 
3). The average variance and intra-individual differences for the other phar-
macodynamic endpoints did not differ between jet injection and conventio-
nal pen administration (table 3), although there was a trend towards greater 
intra-individual CVs for jet injection with respect to T-GIRAUC50% (table 3).  
Table 2 (page 63) - Pharmacodynamic and pharmacokinetic outcome measurements. Data 
are represented as mean ± SEM. T-GIRmax: time until maximal glucose infusion rate. T-GI-
RAUC50%: time until 50% of glucose disposal. GIRmax: maximal glucose infusion rate. Gluc-
total: total amount of glucose administered during the experiment. T-INSmax50%: time until 
50% of maximal plasma insulin value is reached. T-INSmax: time until maximal plasma insulin 
value is reached. T-INSAUC50%: time until 50% of insulin is absorbed. C-INSmax: maximal 
plasma insulin concentration. AUCINS : total area under the plasma insulin concentration cur-
ve. *Standard deviation of the individual mean value of the two test days. #P<0.05. §P<0.001.
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Inter-individual CV (%) Intra-individual CV (%)
Jet injec-
tion
Conventi-
onal pen
Jet injec-
tion
Conventi-
onal pen
P-value
Pharmacodynamics
T-GIRmax, min 37.1 25.2 34.5 ± 5.1 21.2 ± 4.6 0.06
T-GIRAUC50%, 
min
14.8 13.8 9.6 ± 2.0 5.8 ± 2.0 0.08
GIRmax, mg/
kg/min
31.3 28.8 5.6 ± 1.3 8.7 ± 1.8 0.17
Gluctotal, g 29.6 32.0 13.6 ± 2.9 10.0 ± 1.7 0.30
Pharmacokinetics
T-INSmax50%, 
min
30.4 26.9 20.1 ± 5.4 17.5 ± 4.0 1.000
T-INSmax, min 24.8 41.6 15.3 ± 3.3 22.0 ± 4.6 0.25
T-INSAUC50%, 
min
20.2 19.3 9.7 ± 2.4 8.4 ± 2.2 0.540
C-INSmax, 
mU/l
26.4 18.9 15.0 ± 2.5 11.0 ± 2.2 0.24
AUCINS, mU∙-
min∙l-1
21.2 17.0 8.7 ± 1.9 6.0 ± 1.6 0.35
Table 3. Inter- and intra-individual coefficients of variation for jet injection and conventional 
pen.. Data is represented as percentage ± SEM. T-GIRmax: time until maximal glucose infusi-
on rate. T-GIRAUC50%: time until 50% of glucose disposal. GIRmax: maximal glucose infusion 
rate. Gluctotal: total amount of glucose administered during the experiment. T-INSmax50%: 
time until 50% of maximal plasma insulin value is reached. T-INSmax: time until maximal 
plasma insulin value is reached. T-INSAUC50%: time until 50% of insulin is absorbed. C-IN-
Smax: maximal plasma insulin concentration. AUCINS : total area under the plasma insulin 
concentration curve
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This study confirmed that using a jet injector for administration of rapid-ac-
ting insulin advances the onset of insulin’s glucose lowering effect and limits 
the total duration of this effect in comparison to insulin administered by a 
conventional insulin pen. The pharmacological variability of insulin adminis-
tered by the two devices was largely, but not entirely, similar. In particular, 
the time until maximal insulin concentration was less variable after jet in-
jection than after conventional administration, whereas the maximal insulin 
concentration was more variable. There were no differences in the variabi-
lity of other pharmacokinetic endpoints or in that of the pharmacodynamic 
endpoints between the two devices.  
The disparities with regard to the variability of pharmacokinetic parameters 
between insulin administered by jet injection or by conventional means 
were not mirrored by such differences in the more clinically relevant phar-
macodynamic endpoints. Therefore, the play of chance cannot be excluded 
and the implications for clinical practice are probably limited. The intra-in-
dividual CV for the time to maximal glucose-lowering effect (T-GIRmax) 
tended to be somewhat greater after jet than after conventional injection. 
Notably, this greater variability of jet injection was due to the ~40% advan-
cement of insulin’s time-action profile (the denominator of the equation) 
rather than to an actual extension in intra-individual time differences (the 
numerator). The ‘predictability’ of the insulin effect will thus be of similar 
magnitude for the two devices, when used in daily clinical practice.  
Our results extend those of two previous studies that compared the variabi-
lity of regular human insulin administered by jet injection with that by need-
le and syringe (9, 10). One study investigated the variability in insulin levels 
after injection of 10 units of regular insulin in 8 patients with type 1 diabe-
tes. The authors found comparable intra-individual variation in peak insu-
lin levels and time to peak levels for the two injection methods (9), albeit 
slightly higher than what we found with aspart insulin. The second study 
reported comparable intra-individual variability of both insulin effect and in-
sulin action for jet injection and injection by syringes in healthy volunteers, 
based on two glucose clamps, although one of the clamps had a duration 
of only 4 hours (10). Our data are also in line with a study investigating the 
CONCLUSION
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variability of insulin aspart. When injected by syringes in healthy volunteers, 
intra-individual CVs for pharmacodynamic parameters ranged from 11 to 
21% and those for pharmacokinetic parameters from 14 to 16% (8). Finally, 
in a study among patients with type 1 diabetes, the variability in T-INSmax 
for insulin aspart administered by subcutaneous pump was 27% (13). 
The present observations should be seen in the context of the more rapid 
glucose-lowering effect of insulin after jet injection. We have previously 
shown that this reduces the postprandial hyperglycaemic burden and ad-
vances the correction of marked hyperglycaemia in patients with diabetes 
(3). Our findings suggest that these benefits can be sustained with repeated 
injections. This is important, since high variability in the absorption and ac-
tion of insulin impacts on glucose variability, which not only hampers efforts 
to achieve optimal glucose control, but also affects patient’s wellbeing and 
trust in insulin therapy (6).
Limitations of our study include the small sample size, so that we cannot 
prove with statistical certainty that the pharmacological variability of the 
two devices for the administration of insulin are similar. However, since the 
confidence intervals for the main outcome parameters largely overlapped 
(data not shown, but available upon request), such statistical prove may 
have limited relevance for daily clinical practice. Another limitation is that 
the healthy, young volunteers enrolled in this study do not necessarily 
represent the majority of patients, certainly not those with type 2 diabetes. 
However, although variability of the insulin effect may be greater in patients 
with diabetes (6, 14), the impact of clinical parameters on the pharmacoki-
netic variability of rapid-acting insulin has been reported small (13). Finally, 
this study was not designed to assess the impact of other factors on the 
variability of insulin. These factors relate to the site of injection, handling of 
the injection pen and the technique of injecting insulin, all of which may af-
fect variability (15). Notably, the jet injector differs from conventional pens 
in that specific training is required to fill the device with the correct amount 
of insulin, to remove air bubbles from the nozzle, and to apply the right 
amount of pressure when putting the device to the skin.
In conclusion, the variability in glucose-lowering effect is considerable, but 
broadly comparable for jet injection and conventional pen administration. 
When coupled with the approximately 40% advancement in insulin action, 
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CHAPTER 5 
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ABSTRACT
We recently showed in a euglycaemic glucose clamp study among 18 healt-
hy volunteers that using jet injectors rather than conventional pens signifi-
cantly improved the time-action profiles of rapid-acting insulin analogues. 
Here, we investigated whether such profiles were modified by body mass 
index (BMI) and related weight parameters by comparing insulin adminis-
tration by jet injection to that by conventional pen in subgroups defined by 
BMI, waist-to-hip ratio, waist circumference and insulin dose. After conven-
tional administration, times to peak insulin levels (T-INSmax) occurred 31.1 
[95% confidence interval (CI) 13.7–48.5] min later and time to maximum 
glucose requirement (T-GIRmax) 56.9 (95%CI 26.6–87.3) min later in more 
obese (BMI > 23.6 kg/m2) than in lean subjects (BMI < 23.6 kg/m2). In 
contrast, T-INSmax and T-GIRmax were similar in subjects with high and low 
BMI, when insulin was administered by jet injection. We conclude that using 
jet injection for insulin administration may especially benefit subjects with 
higher body weight.
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INTRODUCTION
Most studies investigating the pharmacology of rapid-acting insulin analo-
gues have been conducted in lean subjects, whereas many patients with 
type 1 and the majority of patients with insulin-requiring type 2 diabetes 
are overweight or obese. A high body mass index (BMI) may considerably 
delay the absorption rate and onset of action of regular insulin (1–3) and 
possibly that of rapid-acting insulin analogues. Such delays may be due to 
greater thickness of the subcutaneous tissue at the (abdominal) injection 
site or because higher insulin doses are required (4). A delay in insulin ab-
sorption rate may exacerbate postprandial hyperglycaemia and, because the 
proportional contribution of postprandial glucose to the HbA1c increases 
with lower HbA1c values, interfere with the aim for tight glycaemic control 
(5). 
In a recent study, we showed that jet injectors, which deliver insulin by me-
ans of air pressure instead of a needle, significantly advanced the time-acti-
on profile of the rapid-acting insulin analogue aspart (6). Jet injection results 
in a distinct spray-like dispersion pattern that ensures a larger absorptive 
area and faster penetration through the subcutaneous tissue compared to 
conventional administration by syringes or pens (7). We hypothesized that 
the impact of adiposity on insulin absorption may be less when insulin is ad-
ministered by jet injection. To test this hypothesis, we performed a post hoc 
analysis to assess whether BMI and other body weight parameters modified 
the pharmacology of insulin injected by jet injection.
RESEARCH DESIGN AND METHODS
PARTICIPANTS
Non-smoking healthy adults, aged 18–50 years and with a BMI of 18–28 kg/
m2 were enrolled and asked to provide written informed consent. The study 
was approved by the institutional review board of the Radboud University 
Nijmegen Medical Centre (currently known as Radboud university medical 
center).
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EXPERIMENTAL STUDY DESIGN
The research protocol has been described in detail previously (6). Briefly, all 
participants underwent two 8-h euglycaemic glucose clamps, using a rando-
mized, controlled, double-blind, double-dummy, cross-over study design. 
Venous catheters were placed for administration of dextrose 20% and fre-
quent blood sampling. Insulin aspart (Novo Nordisk, Bagsvaerd, Denmark) at 
a dose of 0.2 U/kg body weight and a comparable volume of placebo soluti-
on (Test Medium Penfill®; Novo Nordisk) were then simultaneously injected 
subcutaneously on both sides of the lower abdomen. On one occasion, insu-
lin was administered by the jet injector (Insujet™; European Pharma Group, 
Schiphol Rijk, the Netherlands) and placebo by conventional pen (NovoPen 
III; Novo Nordisk). On the other occasion, the order was reversed. 
ANALYTICAL PROCEDURES
Plasma glucose levels were determined in duplicate, immediately after 
blood sampling by the glucose oxidase method (Beckmann glucose analyzer 
II; Beckman Instruments, Fullerton, CA, USA). Blood sampled for plasma in-
sulin measurements were centrifuged and stored at −20 °C for later measu-
rement by radioimmunoassay (8).
ENDPOINTS AND CALCULATIONS
The pharmacodynamic and pharmacokinetic endpoints were derived from 
the glucose infusion rate (GIR) and the insulin concentration profile, respec-
tively, and consisted of the time to maximal glucose infusion rate (T-GIRmax) 
and time to maximal insulin concentration (T-INSmax).
STATISTICAL ANALYSES
All data are expressed as means with 95% confidence intervals (95% CIs), 
unless otherwise indicated. Mean outcomes were tested by paired t-tests. 
Pharmacologic data were analyzed in subgroups defined by median BMI 
(highest vs. lowest 50%, n=9 per subgroup) and by analysis of the correlati-
ons between BMI and absorption parameters both as continuous variables. 
Similar analyses were performed with waist circumference (WC),waist-to-
hip ratio (WHR) and insulin dose. Correlations were calculated using the 
Pearson’s correlation test. All statistical analyses were performed by SPSS 
16.0 (Statistical Package for Social Sciences, Chicago, IL, USA). A p-value of 
<0.05 was considered significant.
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RESULTS
Figure 1 - T-INSmax (top) and T-GIRmax (bottom) for the jet injector (Jet, white bar) and 
conventional pen (Conv, black bar) in subgroups of patients with a body mass index (BMI) 
below and above 23.6 kg/m2 (nine participants in every subgroup). *P < 0.05 vs. jet injection 
in similar BMI subgroup; †P < 0.05 vs. BMI <23.6 kg/m2 in same injection group.
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Five men and 13 women were included. Mean age was 27.2 years (range 
19–49 years). The median body weight was 68.6 kg (50.5–93.9 kg), median 
insulin dose administered was 13.7 U (10.1–18.8U), median BMI was 23.6 
kg/m2 (18.1–28.0 kg/m2), median WC was 80 cm(65–98 cm) and median 
WHR was 0.79 (0.67–0.93).
Conventional pen Jet injector
Correlation  
coefficient
P-value Correlation  
coefficient
P-value
BMI
     T-GIRmax 0.556 0.017 0.137 0.592
     T-INSmax 0.597 0.012 0.059 0.815
WHR
     T-GIRmax 0.496 0.037 0.063 0.805
     T-INSmax 0.506 0.032 0.065 0.799
WC
     T-GIRmax 0.557 0.016 0.027 0.914
     T-INSmax 0.563 0.015 -0.012 0.961
Insulin dose
     T-GIRmax 0.542 0.020 0.287 0.249
     T-INSmax 0.419 0.083 0.014 0.954
SUBGROUP ANALYSIS FOR CONVENTIONAL INSULIN PEN
When insulin was injected by conventional pen, T-INSmax was 31.1 (95% 
CI 13.7–48.5) min later and T-GIRmax 56.9 (26.6–87.3) min later in subjects 
with a BMI above the median than in subjects with a BMI below the median 
(figure 1). Similar results were obtained in subgroups defined by WC and 
WHR (data not shown). T-GIRmax was significantly correlated with BMI, 
WC,WHR and insulin dose, and T-INSmax was associated with BMI, WC and 
WHR (Table 1).
 
SUBGROUP ANALYSIS FOR JET INJECTOR
When insulin was injected by the jet injector, neither T-INSmax nor T-GIR-
max differed between subjects with indices of body composition or insulin 
Table 1 - Correlations between pharmacologic parameters and parameters of central obesity 
or insulin dose. WC, waist  circumference; WHR, waist-to-hip ratio
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dose above median values vs. below median values (figure 1). Both T-IN-
Smax and T-GIRmax were unrelated to BMI,WC, WHR or the insulin dose 
(Table 1).
The pharmacologic benefit of jet injection over conventional pen injection 
was proportionally larger in subjects with a high BMI than in those with a 
low BMI. Jet injection reduced T-INSmax by 20.0 (8.5–31.5) min in subjects 
with a BMI below the median and by 47.8 (26.5–69.1) min in subjects with a 
BMI above the median (P=0.018). T-GIRmax was reduced by 29.2 (6.4–51.9) 
min and 79.7 (41.9–117.6) min in subjects with low BMI and high BMI, res-
pectively (P=0.018, figure 1). The bioavailability of insulin, as derived from 
the area under the insulin concentration curve, did not differ between the 
two devices in any of the subgroups. No hematomas or skin redness were 
seen after jet injection.
CONCLUSION
In this post hoc analysis, we show that the pharmacology of rapid-acting 
insulin injected by jet injection is not affected by BMI, WHR and WC. Howe-
ver, in accordance with previous observations in subjects with overt obesity 
(BMI ≥ 30 kg/m2) (1–3), high BMI, WHR and WC were significantly associa-
ted with delays in absorption and onset of action when insulin was adminis-
tered by conventional insulin pen. 
A possible explanation for the dissociation of adiposity indices and insulin 
absorption or action when insulin was administered by jet injection is the 
spray-like dispersion pattern in the subcutaneous tissue, which facilitates 
distribution of insulin over a relatively large absorptive area and therefore 
allows for a more rapid absorption of insulin into the circulation (7). Becau-
se tissue dispersion increases when larger insulin doses are injected, the 
rate of absorption is much less a function of the dose administered than it is 
with conventional pen (4).
A limitation of the present analysis is that it was not pre specified in the 
study protocol. However, our findings with regard to the conventional pen 
are in line with previous studies showing delayed insulin absorption in the 
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obese (3). Other limitations concern the rather narrow BMI range of our 
study population and the fact that patients with diabetes were not investi-
gated. Appropriately designed studies are necessary to confirm these results 
in obese subjects, especially those with (type 2) diabetes and to determine 
whether the long-term effect of these favourable pharmacologic properties 
translate into better glycaemic control and lower risk of (late postprandial) 
hypoglycaemia.
In conclusion, this analysis shows that higher body weight indices or insulin 
dose do not modulate the pharmacological profile of subcutaneous insu-
lin when administered by jet injection, whereas significant delays can be 
observed after insulin administration by conventional pen. As a result, the 
improvement in the pharmacologic profile of rapid-acting insulin injected by 
jet injection appears to be greater for patients with a higher BMI. This may 
be clinically relevant for patients with type 1 or type 2 diabetes who are 
overweight or obese.
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ABSTRACT
Clamp studies have shown that the absorption and action of rapid-acting 
insulin is faster when injected by a jet injector than when administered by 
a conventional pen. To determine whether these pharmacokinetic changes 
also exist in patients with diabetes and benefit postprandial glucose con-
trol, we compared the pharmacologic profile of insulin administration by 
jet injection to that by conventional insulin pen after a standardized meal in 
patients with type 1 or type 2 diabetes.
In a randomized, double-blind, double-dummy cross-over study, 12 patients 
with type 1 and 12 patients with type 2 diabetes received insulin aspart eit-
her by jet injection or by conventional pen followed by a standardized meal. 
Blood was sampled for six hours for determination of glucose and insulin 
levels to calculate pharmacologic profiles.
Insulin administration by jet injection resulted in shorter time until peak 
plasma insulin levels  (51.3 ± 6.4 versus 91.9 ± 10.2 min, P=0.003) and redu-
ced hyperglycaemic burden during the first hour (154.3 ± 20.8 versus 196.3 
± 18.4 mmol∙min∙l-1, P=0.041) when compared to conventional administra-
tion. However, jet injection did not significantly reduce the hyperglycaemic 
burden during the hours thereafter. There was no indication that the jet 
injector performed differently in patients with type 1 or type 2 diabetes.
The considerably more rapid insulin absorption when administered by jet 
injector translates to a significant, albeit modest, decrease in postprandial 
hyperglycaemia in patients with type 1 or type 2 diabetes. The improved 
early postprandial glucose control may specifically benefit patients with 
difficulty limiting postprandial glucose excursions. 
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INTRODUCTION
The pharmacologic profile of rapidacting insulin analogs, although consi-
derablyfasterthanregularinsulin,is still relatively slow compared with the 
profile of endogenous insulin release. As a consequence, patients with type 
1 diabetes or insulin-requiring type 2 diabetes who use these analogs still 
face the risk of immediate postprandial hyperglycemia and late postprandial 
hypoglycemia. In particular, postprandial hyperglycemia has been recogni-
zed as an important contributor to suboptimalglucosecontrol(1), whichmay
explain why the introduction of rapidacting analogs has had little effect on 
HbA1c in people with diabetes (2). Some havethereforesuggested that these 
analogs should be injected at least 15 min before meals (3); however, this 
seems impractical to implement in daily practice. 
 
Pooradherencetoinsulintherapybecause of injection-related anxiety may be 
another, often neglected, reason for failuretoreachglycemictargetswithcur-
rent rapid- and long-acting insulin analogs (4). A sizable proportion ofinsuli-
nusers admit to at least occasionally skipping insulin injections or restricting 
the number of daily injections(4). Although true needle phobia is rare, many 
patients with diabetes perceive insulin injections as painful or experience 
some form of anxiety with injections (5,6), the presence of which is strongly 
associated with nonadherence and poorer glycemic control (7). 
Jet injectors for insulin administration provide a needle-free alternative 
to the use of pens or syringes and were originally developed for patients 
with needle phobia. Administration by jet injection significantly accelerates 
absorption of rapid-acting insulin from the subcutaneous area into the sys-
temic circulation (8). Jet injectors deliver insulin at a high velocity (typically 
.100 m/s) directly across the skin in the subcutaneous tissue and dispense 
the insulin over a larger area than does injection by syringe (9). With the 
euglycemic clamp technique, we recently showed in healthy volunteers that 
administration of insulin aspart by jet injection reduced both the time until 
peak plasma insulin levels and the time to maximal glucose-lowering effect 
by approximately 50% when compared with insulin administered by conven-
tional insulin pen (10). 
Although the euglycemic clamp technique is a reliable method to investigate 
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RESEARCH DESIGN AND METHODS
PARTICIPANTS
Written informed consent was obtained from 12 patients with type 1 and 12 
patients with insulin-treated type 2 diabetes, who were recruited from the 
the outpatient diabetes clinic of the Radboud University Nijmegen Medi-
cal Centre (currently known as Radboud university medical center) and by 
advertisement in a local newspaper. All patients were at least 18 years of 
age, had a body-mass index below 32 kg/m2 and an HbA1c no greater than 
9% (75 mmol/mol). Patients were excluded if they had had a major vascu-
lar event (e.g. myocardial infarction, stroke, symptomatic peripheral artery 
disease, coronary bypass surgery, percutaneous coronary or peripheral 
artery angioplasty) in the past 6 months, used immunosuppressant agents, 
NSAIDs, anticoagulant therapy, oral antidiabetic drugs except metformin for 
type 2 patients, or had symptomatic diabetic neuropathy. Pregnancy was 
excluded where appropriate. The study was approved by the institutional 
review board of the Radboud University Nijmegen Medical Centre.
EXPERIMENTAL STUDY DESIGN
All participants underwent two standardized meal tests, separated by at 
least 2 weeks. Patients were requested to reduce their evening dose of 
insulin or the basal rate of insulin pump administration by 10-20% to avoid 
nocturnal hypoglycaemia and were instructed to consume a low-glycaemic 
index meal on the evening prior to the experimental days. On each experi-
mental day, participants were admitted to the research unit at 07.30 hours 
in fasting condition and having abstained from smoking, alcohol use and 
the pharmacodynamics of therapeutic insulin, it cannot be used to predict 
the glucose-lowering effect of insulin when injected before a meal, particu-
larly in patients with diabetes. The aim of the current study was therefore 
to investigate the pharmacology of insulin injected by jet injector before 
a standardized meal in patients with type 1 diabetes and insulin requiring 
type 2 diabetes. We also wanted to investigate whether patients would 
perceive insulin administration with the current jet injector device as more 
or less painful as insulin injection by pen.
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caffeine use for at least 24 hours. Patients on subcutaneous insulin pumps 
were asked to stop the pump. The experiments were performed in supine 
position in a temperature-controlled room (22–24°C). Two catheters were 
inserted intravenously. One catheter was inserted in retrograde fashion 
in a dorsal hand vein for blood sampling, kept patent by placing the hand 
in a heated box at 55°C (11). The other catheter was placed in an antecu-
bital vein of the contralateral arm for insulin and glucose administration. 
After obtaining baseline variables, low-dose insulin was infused to achieve 
normoglycaemia, after which insulin infusion was either terminated or, for 
patients treated with insulin pumps, continued at a rate corresponding to 
the basal rate of the patient’s insulin pump. 
Thirty minutes after achieving stable normoglycaemia, patients received 
insulin (aspart, Novo Nordisk, Bagsvaerd, Denmark) either by jet injection 
(Insujet, European Pharma Group bv, Schiphol-Rijk, the Netherlands) or 
by conventional insulin pen (NovoPen III, Novo Nordisk) and a comparable 
volume of placebo solution (Test Medium PenFill, Novo Nordisk, Bagsvaerd, 
Denmark) by the alternate device in a double-blind fashion, both injected 
subcutaneously in the abdomen. On the other occasion, the devices contai-
ning the insulin and placebo solution were reversed. Thus, all participants 
received both insulin and placebo on the two experimental days (“double 
dummy”). The dose of insulin was individualized to the patient’s usual pran-
dial insulin requirements and averaged 17.6 ± 3.9 units (range 8 to 40 units, 
16.3 ± 3.9 units for patients with type 1 DM, 18.9 ± 11.1 units for patients 
with type 2 DM, P=0.44). Two-by-two block randomization was used to 
randomize the sequence by which the two devices were used for insulin and 
placebo injections. To assure blinding, both pen devices were prepared by a 
nurse, who was not otherwise involved in conducting the experiments. Insu-
lin administration with both devices was performed by trained staff only, as 
described in detail previously (10).
One minute after insulin administration, the participant consumed a stan-
dardized meal consisting of 3 white sandwiches with marmalade and honey 
and a glass of orange juice (total energy 538 kcal, 108 g carbohydrates, 7 
g fat, 11 g protein) in 10-15 minutes. Plasma glucose measurements were 
measured at 5-min intervals during the first 3 hours of the study and at 10-
min intervals for another three hours. Blood for plasma insulin levels was 
sampled every 5 min during the first hour, every 15 min for the second hour, 
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and  every 30 minutes thereafter. When plasma glucose values dropped be-
low 4.8 mmol/L, 20% dextrose was administered intravenously to maintain 
normoglycaemia. On the second experimental day, patients were asked to 
rate the amount of discomfort or pain experienced with the different admi-
nistration methods on a visual analogue scale (VAS) from 0 to 10 cm and to 
indicate which device they would prefer, should they have a choice.  
All pharmacologic parameters were derived from the plasma glucose and in-
sulin levels. With respect to the pharmacokinetics, we calculated the time to 
maximal insulin concentration (T-INSmax), the maximal insulin concentrati-
on (C-INSmax), the area under the insulin concentration curve (INSAUC) and 
the time until 50% of insulin absorption (T-INSAUC50%).  We also calculated 
the times until reaching 50% of the T-INSmax (T-INSmax50%) and reaching 
the same value when insulin levels declined (T-INSdec50%). The pharmaco-
dynamic parameters consisted of the area under the baseline-subtracted 
plasma glucose concentration time-curve during the first hour (BG-AUC0–
1h) and first 2 hours (BG-AUC0–2h) after insulin injection, representing the 
initial glycaemic load, the maximal glucose excursion (BGmax), the area 
under the total baseline-subtracted plasma glucose concentration time-cur-
ve (BG-AUC0–6h) and the time until plasma glucose had returned to base-
line (T-BGBL). Safety parameters included the number of patients requiring 
exogenous glucose infusion to prevent postprandial hypoglycaemia, the 
amount of exogenous glucose required and the duration of time that exo-
genous glucose was required.
ANALYTICAL PROCEDURES
Plasma glucose was measured by the glucose enzymatic-amperometric me-
thod (Biosen C-line GP+, EKF-diagnostic GmbH, Barleben, Germany) during 
the experiments. Blood sampled for determination of plasma insulin levels 
was collected in lithium-heparin tubes. After centrifugation, the supernatant 
was stored at -20°C. Plasma insulin was measured by radioimmunoassay 
(RIA) (12).
POWER CALCULATION AND STATISTICAL ANALYSES
All data are expressed as means ± SEM, unless otherwise indicated. Mean 
outcomes for all study endpoints and most safety endpoints were tested 
by paired T-tests. A Chi2 test was used to compare the number of patients 
requiring exogenous glucose with the two injection devices. Continuous 
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data were tested for normal distribution (Shapiro–Wilk test and Kolmogor-
ov-Smirnov test) and subsequently analyzed using repeated measures 
ANOVA (Wilks’ Lambda test), with the device as between-subject factor. A 
P-value of <0.05 was considered statistically significant. All statistical analy-
ses were performed using SPSS (Statistical Package for the Social Sciences, 
version 18.0, International Business Machines Corporation, Armonk, New 
York, USA).
RESULTS
Whole Group Type 1  
diabetes
Type 2  
diabetes
Male-to-female ratio 20:4 9:3 11:1
Age* (years) 49.9 ± 16.0 39.2 ± 16.2 60.6 ± 7.2
BMI (kg/m2) 2.4 ± 2.1 25.7 ± 31.9 27.0 ± 2.1
HbA1c (%) 7.5 ± 0.8 7.3 ± 1.0 7.7 ± 0.6
Daily insulin dose (units) 57.2 ± 32.5 48.6 ± 15.2 65.1 ± 42.0
Duration of diabetes 
(years)
18.3 ± 11.9 21.5 ± 15.0 15.2 ± 7.0
Systolic blood pressure 
(mmHg)
135.1 ± 12.2 127.5 ± 8.7 142.7 ± 10.7
Diastolic blood pressure 
(mmHg)
76.9 ± 10.2 75.2 ± 9.7 78.6 ± 10.8
Insulin regimen
   Insulin pump 2 5 0
   Multiple daily  
   injections
17 7 10
   Pre-mixed insulin 2 0 2
   Use of metformin 8 0 8
Table 1 – Baseline characteristics. Data are presented as number, mean ± SD. *P<0.05 for 
comparison between patients with type 1 and 2 diabetes
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Table 2 - Pharmacokinetic and pharmacodynamic parameters for insulin administration
with the jet injector and the conventional insulin pen. Data are mean 6 SEM. T-INSdec50%, 
time to reach 50% of the C-INSmax as insulin levels declined;T-INSmax50%, time to reach 
50% of the C-INSmax as insulin levels rose; T-BGBL, time until plasma glucose had returned to 
baseline.
Table 1 summarizes baseline characteristics of the participants. All 24 
subjects completed the meal tests. However, the first test had to be resche-
duled in two subjects. In one instance, the insulin dose administered was 
erroneously calculated too low. In the other instance, the spring of the jet 
injector released prematurely, so that it could not be assessed how much 
insulin (or placebo) had actually crossed the skin, if any. The jet injector was 
subsequently returned to the manufacturer and replaced.
Jet Injector Conventional 
pen 
P-value
Pharmacokinetic parameters
     T-INSmax50% (min) 13.9 ± 1.3 31.8 ± 3.2 <0.001
     T-INSmax (min) 51.3 ± 6.4 91.9 ± 10.2 0.003
     T-INSAUC50% (min) 107.8 ± 5.5 123.1 ± 5.7 0.011
     C-INSmax (mU/L) 98.8 ± 8.9 103.3 ± 8.4 0.53
     T-INSdec50% (min) 143.3 ± 9.3 165.6 ± 10.0 0.0497
     C-INSAUC (pmol∙min∙L-1) 11,282 ± 
966.5
11,791.4 ± 
1,063.8
0.57
Pharmacodynamic parameters
     BG-AUC1h (mmol∙min∙L-1) 154.3 ± 
20.8
196.3 ± 18.4 0.04
     BG-AUC2h (mmol∙min∙L-1) 475.5 ± 
68.0
554.4 ± 65.7 0.18
     BG-AUC6h (mmol∙min∙L-1) 1,283.8 ± 
134.6
1,360.5 ± 147.1 0.64
     BGmax (mmol/l) 12.6 ± 0.84 13.3 ± 0.82 0.36
     BGmax  - baseline (mmol/l) 7.0 ± 0.8 7.9 ± 0.8 0.27
     T-BGbl (min) 216.1 ± 
17.54
223.3 ± 17.79 0.58
     Exogenous glucose (g) 22.2 ± 5.9 23.3 ± 5.9 0.77
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Figure 1 - Changes from baseline during the standardized meal test. Top: changes in plasma 
insulin levels after insulin administration by jet injector (open circles) and conventional pen 
(black squares). Bottom: changes in plasma glucose levels after insulin administration by jet 
injector (open circles) and conventional pen (black squares)
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PHARMACOKINETIC ENDPOINTS
Plasma insulin levels at initiation of insulin injections were slightly higher for 
the experiments where the conventional pen was used than those for the 
jet injector (22.8 ± 2.5 versus 19.4 ± 2.4 mU/l, P=0.037). Thereafter, plasma 
insulin levels increased faster when insulin was injected by the jet injec-
tor than when injected by conventional pen (table 2). The time until peak 
plasma insulin concentrations was advanced from 91.9 ± 10.2 minutes with 
the conventional pen to 51.3 ± 6.4 minutes with the jet injector (P=0.003), 
a difference of 40.6 ± 12.3 minutes (figure 1, table 2). Also, the times until 
50% absorption of the insulin dose (T-INSAUC50%) and for insulin levels to 
decline after reaching peak values were significantly shorter when insulin 
was administered by jet injection rather than by conventional pen (table 
2). In contrast, the total amount of insulin being absorbed over the entire 
period of six hours, as reflected by the time under the insulin concentration 
curve (INSAUC), did not differ between the two devices.
 
PHARMACODYNAMIC ENDPOINTS 
There were no differences in plasma glucose values between the two expe-
rimental conditions, neither at baseline (10.5 ± 0.6 versus 10.8 ± 0.7 mmol/l, 
P=0.65), nor directly prior to the experiments (5.61 ± 0.13 versus 5.45 ± 
0.18 mmol/l, P=0.49). The time-action curves for the plasma glucose level 
after meal ingestion were significantly different between the two devices 
(P=0.018 (ANOVA)). In line with the faster insulin pharmacokinetics, the 
hyperglycaemic burden during the first hour, as reflected by the area under 
the glucose concentration curve (BG-AUC0–1h) was significantly reduced 
when insulin was administered by the jet injector rather than by the con-
ventional pen (figure 2, table 2). This benefit favoring the jet injector over 
the conventional insulin pen was no longer apparent after two hours (table 
2). Although glucose values tended to be lower in the late postprandial 
phase after conventional pen administration, there were no significant diffe-
rences between the two devices with regard to the maximal glucose value, 
maximal glucose increment or area under the six-hour glucose concentrati-
on curve (Table 2). 
SAFETY
There were no differences between the jet injector and conventional pen 
with respect to number of patients requiring exogenous glucose to prevent 
hypoglycaemia (17 versus 18, P=0.75), the timing of initiation of glucose 
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administration (180 versus 194 minutes, P=0.79) or the amount of gluco-
se administered (21.0 ± 5.5 g versus 23.7± 5.7 g, P=0.61). Both injection 
methods were well tolerated and elicited a similar experience of pain or 
discomfort (VAS, 1.96 versus 1.40, P=0.14). Thirteen patients out of the total 
of 24 preferred the conventional pen over the jet injector, four preferred the 
jet injector and six remained indifferent. One patient did not complete the 
questionnaire. 
SUBGROUP ANALYSIS
The pharmacodynamic benefit of insulin administration by jet injection see-
med numerically higher in patients with type 2 diabetes, but the difference 
was not statistically different between patients with type 1 or type 2 diabe-
tes. BG-AUC0–2h was 478 ± 117 mmol∙min∙l-1 after jet injection versus 500 
± 98 mmol∙min∙l-1 after conventional administration for type 1 diabetes, 
P=0.87, and 471 ± 82 versus 662 ± 96 mmol∙min-1∙l-1 for type 2 diabetes, 
P=0.09, figure 3). There were no differences in subgroups defined by age, 
sex or BMI (data not shown).
Figure 2 - The 2-h BG-AUC values for the jet injector (white bars) and conventional pen (black 
bars) in subgroups according to type of diabetes. *P = 0.09 vs. jet injection in similar BMI 
subgroup
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Previously, we showed in young healthy volunteers that absorption and 
action of aspart insulin occurred twice as fast when administered by jet 
injection than by conventional pen (10).  The present study confirms a more 
rapid absorption of insulin aspart when administered by the current jet 
injector compared to conventional pen in patients with type 1 and type 2 
diabetes. These pharmacokinetic properties translated into a significant, 
albeit modest, decrease in early (i.e. first 60 minutes) postprandial hypergly-
caemia after a standardized meal rich in carbohydrates. Beyond one hour, 
the benefit of jet injection on postprandial glycaemic burden was no longer 
statistically significant. 
Considering the substantial enhancement of insulin action by jet injection in 
our clamp study (10) and the current improvement of insulin absorption, we 
anticipated a sizeable pharmacodynamic benefit of insulin administration 
by jet injection in the current study. Although the lower “early” postprandial 
glucose levels and tendency towards lower glucose levels in the later post-
prandial phase confirmed the results of the clamp study in a more ‘real-life’ 
situation, the effects were rather modest. This partial discrepancy may be 
explained first by the relatively large variation, both inter- and intra-indivi-
dually, in glucose excursions after the meal test. Indeed, maximal glucose 
excursions varied between 5.9 and 22.9 mmol/l among subjects and bet-
ween 0.1 and 12.9 mmol/l within subjects. Glucose levels at admittance at 
the research unit were similarly variable, although all patients consumed a 
low-glycaemic index supper on the evening before the experiments. Factors 
contributing to this large variation may include the heterogeneity of the 
participants, the suboptimal glycaemic control and the fact that all partici-
pants, including those with type 2 diabetes, used insulin.  
A second explanation concerns the finding that insulin absorption was much 
slower in the patients compared to what we had previously observed in 
healthy volunteers (10). Although jet injection advanced insulin absorption 
to about similar extent in both groups, insulin levels peaked substantially 
later in subjects with than in those without diabetes (51.3 versus 30.6 mi-
nutes, P=0.012). Since the standardized meal consisted mainly of high-gly-
caemic index carbohydrates, insulin absorption may have been too slow to 
sufficiently counteract the fast glucose load absorption. Whether jet injec-
CONCLUSION
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tion would have performed better for a more usual mixed meal with slower 
food absorption cannot be determined from our data. Parenthetically, most 
patients in our study admitted to never consume high-glycaemic index car-
bohydrates in such large quantities to avoid extreme glucose excursions. 
Why rapid-acting insulin absorption is slower in patients with diabetes 
compared to subjects without diabetes is unknown. We previously showed 
a strong association between BMI and rate of insulin absorption in healt-
hy subjects, arguing a role for greater subcutaneous tissue thickness (13). 
However, in the current patient group, insulin absorption was unrelated to 
the BMI or any other measure of body composition. The presence of insulin 
antibodies, commonly found in patients on long-term insulin therapy, has 
been suggested to attenuate the absorption of subcutaneous insulin (14). 
Insulin antibodies were, however, not measured in our study. Alternatively, 
subcutaneous adipose tissue blood flow (ATBF) may also affect the absorpti-
on of insulin (15). Reduced subcutaneous ATBF has been reported in over-
weight non-diabetic subjects (16), as well as in patients with type 1 (17, 18) 
or type 2 diabetes (19). Also, ATBF may fail to increase to dietary stimuli in 
overweight subjects (16) and in patients with type 2 diabetes (19).  
Although the pharmacodynamic benefit of jet injection appears small, it is 
of potential clinical relevance for patients with early postprandial glucose 
excursions not sufficiently covered by conventional insulin injections. Admi-
nistration of rapid-acting insulin by this jet injector may especially represent 
a valuable alternative for patients with type 2 diabetes in whom the post-
prandial glycaemic benefit of jet injection tended to be more pronounced 
than in those with type 1 diabetes. Parenthetically, a device that performs 
at least as good as or – if anything – potentially better than conventional 
pens, may be a good option for any patient not tolerating insulin injections 
by needles or regarding these as otherwise uncomfortable. A recent survey 
showed that 28.6% of patients with type 2 diabetes perceive insulin injecti-
ons as painful (20), making such patients at high risk of skipping injections, 
at least occasionally (7). Upon asking, most patients still preferred the con-
ventional pen over the jet injector. However, patients were unselected, ge-
nerally tolerated conventional injections without discomfort, consequently 
felt no need to change the mode of administration, and did not handle the 
jet injector (or the conventional pen) themselves under study conditions. 
Future research will need to reveal patient’s tolerability of the jet injector 
after personal experience with the device in daily practice and over a longer 
time period.  
Handling of a jet injector may be more cumbersome than that of a conventi-
onal insulin pen. It requires sufficient training in air-free filling of the cham-
ber with insulin and correct placement of the injector on the skin to assure 
that the entire volume of insulin reaches the subcutaneous compartment. 
Inadequate contact between injector and the skin has been reported to re-
sult in bruises and ‘wet’ injections, leading to discomfort and unpredictable 
insulin absorption profiles (21). Importantly, the current device has a built-in 
lock/release system that only releases insulin when proper skin contact has 
been made and sufficient pressure has been applied to the nozzle of the 
injector. Other factors that determine optimal insulin delivery relate to jet 
velocity and nozzle diameter (22-24). Our data are therefore in part specific 
for the jet injector used and cannot be extrapolated to other jet injectors.  
Various strategies are currently under development to enhance absorption 
and action of subcutaneous insulin. These strategies include local skin hea-
ting to stimulate tissue perfusion (25), co-administration with hyaluronidase 
to break the solidity of the extracellular matrix (26), and destabilizing insulin 
hexamer formation by addition of EDTA and citric acid (27). The pharmaco-
kinetic and pharmacodynamic benefit of these interventions are more or 
less comparable with those of jet injection and range from ~10% to ~60% 
advancement of peak insulin levels and maximal glucose lowering effect. A 
difference between jet injection and other developments to enhance insulin 
absorption is that the first is already available for clinical application, whe-
reas the latter are in still in various stages of development and have not yet 
been marketed.  
In the present study, we found that jet injection accelerated the absorption 
of insulin aspart patients with type 1 and insulin-treated type 2 diabetes. 
This better pharmacokinetic profile was initially followed by a congruent 
reduction in glucose excursions after a high-glycaemic index meal, in parti-
cular during, but not beyond the first hour. Jet injection may therefore be a 
good needle-free alternative to conventional insulin pens of at least equi-
valent pharmacological efficacy for the administration of insulin in patients 
with diabetes. Future research is needed to determine whether better 
pharmacologic properties of insulin injection by jet stream translate into 
beneficial long-term effects on glycaemic control and risk of hypoglycaemia 
in patients with diabetes.
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CHAPTER 7 
INSULIN ADMINISTARED BY NEEDLE-FREE JET INJECTION  
CORRECTS MARKED HYPERGLYCAEMIA FASTER IN  
OVERWEIGHT OR OBESE PATIENTS WITH DIABETES
HELENA M. DE WIT, ELSEMIEK E.E.C. ENGWERDA, CEES J. TACK, BASTIAAN E.  
DE GALAN. DIABETES OBES METAB. 2015;17(11):1093-9
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ABSTRACT
Rapid correction of marked hyperglycaemia in patients with diabetes is 
important to reduce the hyperglycaemic burden and prevent metabolic 
disruption. Insulin administered by jet injection is more rapidly absorbed 
than when injected by a conventional pen. We therefore tested whether jet 
injection resulted in faster correction of marked hyperglycaemia than when 
insulin is injected by a conventional pen. 
Adult, overweight or obese (BMI ≥25 and ≤40kg/m2) patients with type 
1 diabetes (n=10) or insulin-treated type 2 diabetes (n=10) were enrolled 
in a randomized, controlled, cross-over study. On two separate occasions, 
patients were instructed to reduce insulin dose(s) to achieve marked hyper-
glycaemia (18-23mmol/l). Subsequently, insulin aspart was administered 
either by jet injection or by conventional pen, in a dose based on estimated 
individual insulin sensitivity. Pharmacodynamic and pharmacokinetic pro-
files were derived from plasma glucose and insulin levels, measured for six 
hours after injection. 
After conventional injection, plasma glucose concentration dropped 
≥10mmol/l after 192.5 ± 13.6 minutes . The jet injector advanced this time 
to 147.9 ± 14.4 minutes (difference 44.6 [95%CI 4.3-84.8]; P=0.03), except 
in 3 patients who failed to reach this endpoint. The time advantage excee-
ded 1.5 hours in patients with a BMI above the median. Jet injection also 
reduced the hyperglycaemic burden during the first two hours (2042 ± 37.2 
vs. 2168 ± 26.1 mmol∙min∙l-1; P=0.01) and the time to peak insulin levels 
(40.5 ± 3.2 vs. 76.8 ± 7.7 minutes, P<0.001), but did not increase the risk for 
hypoglycaemia. 
Administration of rapid-acting insulin by jet injection results in faster correc-
tion of marked hyperglycaemia in overweight or obese patients with insu-
lin-requiring diabetes.
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INTRODUCTION
Hyperglycaemia frequently occurs in patients with diabetes and significantly 
affects overall glycaemic control, even when elevated glucose levels exist 
only for a short period of time (1). When considerable, hyperglycaemia 
may cause symptoms, e.g. thirst, dizziness or headache, and predispose to 
severe metabolic disturbances when not corrected quickly. The correction 
of marked hyperglycaemia is often difficult, because glucose toxicity resul-
ting from hyperglycaemia may induce insulin resistance, leading to a higher 
insulin dose requirement. Moreover, high insulin doses are probably more 
slowly absorbed than smaller doses (2), which may prolong the time spent 
in hyperglycaemia and tempt the individual to repeat the insulin injection, 
resulting in an increased risk of late hypoglycaemia. 
Insulin administration by jet injection is a needle-free alternative to con-
ventional injections, which delivers insulin at high velocity (typically >100 
m/s) across the skin, dispensing it over a larger subcutaneous area than 
insulin injected with a needle (3). This method of insulin administration, 
first developed n the 1950s (4), significantly accelerates insulin absorption 
from the subcutaneous tissue into the systemic circulation, resulting in a 
more direct onset and shorter duration of insulin action as compared with 
insulin injected with a needle (3–10). We recently compared the efficacy of 
a contemporary jet injector (Insujettm;EuropeanPharmaGroup,Schiphol-Rijk, 
The Netherlands) with that of a frequently used conventional insulin pen for 
the administration of a rapid-acting insulin analogue. Both in healthy parti-
cipants without diabetes and in patients with type 1 or insulin-treated type 
2 diabetes, the jet injector considerably advanced insulin absorption and 
its subsequent glucose-lowering effect (11,12). Furthermore, jet injection 
reduced the hyperglycaemic burden after a standardized meal (12).
The shorter time–action profile of insulin administered by jet injection may 
be especially advantageous for the correction of marked, potentially hazar-
dous, hyperglycaemia. We therefore hypothesized that insulin administered 
by jet injection would result in more immediate and faster correction of 
marked hyperglycaemia than insulin administered by a conventional insulin 
pen. Because the rate of absorption of insulin injected by jet stream is much 
less affected by higher insulin doses and body weight than insulin injected 
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conventionally (12,13), the aim of the present study was to test this hypo-
thesis in patients with type 1 diabetes or insulin-treated type 2 diabetes 
who were either overweight or obese. We also aimed to compare the phar-
macokinetics, safety and ease of use of both modes of insulin administrati-
on.
RESEARCH DESIGN AND METHODS
This randomized, controlled, cross-over study was conducted at the Rad-
boud university medical center between March and October 2014. The 
study was approved by the institutional review board of the Radboud uni-
versity medical center and conducted according to Good Clinical Practices. 
All participants provided written informed consent and received a reimbur-
sement. 
PARTICIPANTS
Potentially eligible subjects with type 1 or type 2 diabetes were selected 
from the Radboud university medical center outpatient diabetes clinic or 
recruited by social media. They were men or women aged 18-75 years, 
with a body-mass index (BMI) of ≥25 and ≤40 kg/m2 and haemoglobin A1c 
(HbA1c) of ≥6.5 and ≤10% (≥48 and ≤86 mmol/mol), who were treated with 
basal-bolus insulin for at least 12 months, either by multiple daily injections 
with basal and prandial insulin or by subcutaneous insulin pump. Exclusion 
criteria were insulin requirement of <34 or >200 units per day (based on 
the minimum and maximum amount of insulin that could be injected by jet 
injection), use of oral antidiabetic agents or drugs known to interfere with 
glucose control other than metformin (a 4-week wash-out of thiazolidinedi-
ones, sulphonylurea, and DPP-4 inhibitors was allowed), known allergy to 
aspart insulin, symptomatic diabetic neuropathy, history of a major cardio-
vascular event in the previous six months, liver enzymes ≥3.0 times the up-
per normal limit, plasma creatinine >150 μmol/l, anemia (hemoglobin <7.5 
or <8.3 mmol/l for females and males, respectively) and pregnancy.
RANDOMIZATION AND STUDY PROCEDURES
The participants who were enrolled underwent two separate test days. 
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Experiments started at 7.30 AM, with the patient in fasting condition, 
and having abstained from smoking, alcohol use, and caffeine-containing 
substances for 24 hours prior to the experiments. On the day before the 
experiments, patients were instructed to interrupt or reduce the use of 
long-acting insulin and short-acting prandial insulin in order to reach hyper-
glycaemia, targeting next-morning plasma glucose values of 15-18 mmol/l. 
Patients with insulin pumps were instructed to reduce the basal rate the 
evening and night before the experiment, and to stop the pump two hours 
before the experiment. Reductions in insulin dose were determined on an 
individual basis, and instructions were given to inject short-acting insulin 
according to an individualized schedule if glucose levels exceeded 18-20 
mmol/l up to two hours before arrival at the research unit. 
The experiments were performed with the patient in supine position in a 
temperature-controlled room (22–24°C). First, a catheter was inserted in re-
trograde fashion in a dorsal hand vein for frequent blood sampling, whereby 
the hand was placed inside a heated box (~55°C) to arterialize venous blood 
(14). Next, plasma glucose was measured to determine whether the glucose 
level was in the target range of 18-23 mmol/l. In case the glucose value was 
too low, we either (1) awaited the spontaneous rise in plasma glucose for 
a maximum of three hours; (2) administered soda drink and subsequently 
waited for a minimum of 45 minutes until glucose levels had stabilized in 
the target range; or (3) postponed the experiment if we expected that the 
glucose target was unattainable within three hours. 
After a stable plasma glucose level in the target range was obtained (as de-
termined by 2-3 glucose values measured within a 15 minute interval with 
a less than 2 mmol/l difference), the required insulin dose was calculated 
as the number of units required to reduce the plasma glucose value to 6 
mmol/l, using the following formula: 
Insulin dose = ([glucose - 6] ÷ [ISF]) x 1.5     (1)
In which glucose is the measured glucose value in mmol/l and ISF the insulin 
sensitivity factor, reflecting the expected fall in plasma glucose after admi-
nistration of one unit of insulin, and calculated by dividing 100 by the total 
daily insulin dose (TDID) (15). We used a multiplicity factor of 1.5 to ensure 
that sufficient insulin was administered to overcome hyperglycaemia-in-
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duced glucose toxicity and rounded the outcome up to the nearest round 
number or to a maximum of 40 units, as this was the maximum single dose 
the jet injector could inject. The calculated dose of aspart (Novorapid, Novo 
Nordisk, Bagsvaerd, Denmark) was administered subcutaneously in the 
abdomen either by jet injection (InsujetTM; European Pharma Group bv, 
Schiphol-Rijk, the Netherlands) or by conventional insulin pen (Flexpen®; 
Novo Nordisk). The InsujetTM jet injector delivers insulin across the skin 
with a short ‘click’ of 50-60 dB. The sequence by which the two devices 
were tested was randomized (1:1) by blocks of two according to diabetes 
type, using a computer-generated random number list. All participants were 
trained to use both devices. When possible (with the dominant hand free 
from cannulation), the injection was given by the participant under supervi-
sion of the research staff, as previously described (11). 
Following insulin administration, plasma glucose was measured on site with 
the glucose enzymatic-amperometric method (Biosen C-line GP+; EKF-diag-
nostic GmbH, Barleben, Germany), at 5-minute intervals for the first three 
hours, and at 10-minute intervals for the subsequent three hours. Also, 
blood was drawn, processed, and serum was stored at -80°C for later deter-
mination of plasma insulin levels by radioimmunoassay every 10 minutes 
during the first hour, every 15 minutes during the second hour, and every 30 
minutes thereafter (16).
 
When glucose values dropped below 4.8 mmol/l, glucose 20% was infused 
intravenously through another catheter that was placed as needed, to pre-
vent hypoglycaemia. Within 30 minutes after insulin injection, a question-
naire was administered, asking participants to point out on a numeric rating 
scale from 0 to 10 the amount of discomfort or pain and the ease of use 
experienced with the tested administration method, and the device they 
would prefer for insulin injection should they have a choice. Six hours after 
the insulin injection, the experiments were terminated, and the patients 
were given a meal. Two to four weeks later, the second experimental day 
was scheduled, following the same procedure and testing the other device. 
OUTCOME MEASURES
The primary endpoint was the time needed to achieve a drop in plasma 
glucose concentration of ≥10 mmol/l (T-BG≥10). Secondary pharmacody-
namic endpoints included the time in minutes until plasma glucose values 
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had dropped below 10 mmol/l (T-BG10) and 5 mmol/l (T-BG5); the slope 
of the glucose fall (Rfall), calculated from the time-glucose curve; and the 
hyperglycaemic burden for the first 2 hours (BG-AUC0-2h) and total 6 hours 
(BG-AUC0-6h) post-injection, reflected by the areas under the two- and six-
hour time-glucose curves, respectively. Secondary pharmacokinetic end-
points were the time to maximal insulin concentration (T-INSmax); maximal 
insulin concentration (C-INSmax); the area under the baseline-corrected 
insulin-concentration curve (INSAUC), reflecting total insulin absorption; 
and the time until 50% of insulin absorption (T-INSAUC50%). Tolerability was 
tested by the amount of discomfort or pain and the ease of use experienced 
with the two administration methods using a numeric rating scale, and the 
proportion of subjects preferring the jet injector for insulin administration. 
Safety was tested by the number of patients requiring exogenous glucose 
infusion to prevent hypoglycaemia (blood glucose ≤4.8 mmol/l) after insulin 
injection, the amount of exogenous glucose required, and the duration of 
glucose administration.
STATISTICAL ANALYSIS
Since we previously found a 29.2 ± 42.1 minutes (~25%) reduction in time to 
achieve a similar glucose lowering effect over the first 2 hours after admi-
nistration of a standard insulin dose by jet rather than conventional injec-
tion (11), we calculated that 17 participants would be required to detect a 
~30-minute reduction in time to achieve the primary endpoint with 80% sta-
tistical power at a 5% level of significance. To correct for the relatively small 
number of subjects involved, a total of 20 subjects were enrolled, and addi-
tional participants were recruited in case of drop-out. To perform subgroup 
analyses, we enrolled an equal number of patients with type 1 and type 2 
diabetes. All data are expressed as mean ± SE; differences are expressed as 
means with 95% confidence intervals (95% CIs), unless otherwise indicated. 
Paired t tests (or Wilcoxon signed-rank tests for nonparametric data) were 
performed to compare most study endpoints; in case of missing data for 
one of the pairs, e.g. when an endpoint was not reached, we performed 
unpaired t tests (or Mann-Whitney U tests). Glucose and insulin values for 
the two devices were analyzed with two-way repeated measures ANOVA. 
The chi-square test or Fisher exact test was used as appropriate for analysis 
of differences in categorical variables. Subgroup analyses were performed 
using a linear mixed model, with fixed effects for device-by-subgroup inter-
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RESULTS
action. Data were entered in a validated data management system (MACRO; 
InferMed Ltd, London, UK), and analyzed according to intention to treat, 
using SPSS 20.0 (IBM SPSS Statistics for Windows, Version 20.0, IBM Corp, 
Armonk, NY). P<0.05 was considered statistically significant.
A total of 26 patients with diabetes were screened, 23 of whom were inclu-
ded. Two were not eligible because they did not meet HbA1c criteria, and 
one was excluded because of anaemia.  After inclusion, three subjects were 
excluded and subsequently replaced: one participant did not reach hyper-
glycaemia after interrupting insulin administration for 72 hours, and two 
participants withdrew consent after the first experimental day was postpo-
ned, because of not reaching the hyperglycaemic target. Baseline charac-
teristics of all subjects who underwent testing are displayed in Table 1. In 
three cases, the experiment was rescheduled: in one patient, the insulin 
dose was erroneously calculated too low, and in two cases the jet injector 
produced a ‘wet injection’, i.e. insulin was released before the injector made 
proper contact with the skin. Two additional experiments were postponed 
because the first measured plasma glucose value was <10 mmol/l. In 13 ex-
periments (7 with a jet injector and 6 with the conventional pen; 10 among 
6 patients with type 2 diabetes and 3 among 2 patients with type 1 diabe-
tes), participants were given soda drink in order to reach the hyperglycae-
mic target. In half of the experiments, the patient operated the jet injector.   
Mean (± SD) glucose values prior to insulin injection were 20.6 ± 2.5 and 
21.3 ± 2.8 mmol/l for patients with  type 1 and type 2 diabetes, respectively. 
These data were used to calculate the required insulin doses at 14.3 ± 5.9 
and 29.1 ± 11.5 units. As the glucose values at baseline (at the moment of 
insulin injection) differed slightly, but significantly, between the jet injector 
and conventional pen (22.2 ± 0.6 vs. 20.4 ± 0.5 mmol/l, P=0.004), we used 
the change in glucose levels rather than absolute values for analyses con-
cerning the area under the glucose curve and time to reach glucose values 
below 10 and 5 mmol/l.
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Table 1 - Baseline characteristics. Data are expressed as mean ± SD, unless otherwise indica-
ted
Type 1 diabetes Type 2 diabetes
Sex, male:female 7:3 7:3 
Mean age, years 48 ± 12 59 ± 7
Diabetes duration, years 28.7 ± 11.9 17.8 ± 8.2 
Insulin treatment duration, 
years, median (range)
28.9 (8.5 - 45.3) 10.9 (7.2 - 19.6)
Body weight, kg 93.8 ± 12.0 106.2 ± 15.8
BMI, kg/m2 29.7 ± 3.7 34.7 ± 4.3 
Waist circumference, cm 99.7 ± 5.5 111.1 ± 17.1
HbA1c, % (mmol/mol) 8.4 ± 1.1 (68 ± 12) 8.7 ± 1.1 (72 ± 12)
Insulin dose, Units/day, medi-
an (range)
57 (34-109) 136 (36-200)
Insulin regimen, n 
   Basal-bolus 4 8
   Pump therapy 6 2
Oral medication, n 
   Metformin only 1 3
   Metformin and DPP-4  
   inhibitor
0 1
   Thiazolidinedione 0 1
Current smoker, n 0 2
PHARMACODYNAMIC ENDPOINTS
The fall in plasma glucose values during the experiments is displayed in 
Figure 1A, the slope of which was significantly steeper with the jet injector 
than with the conventional pen (Table 2). The time until plasma glucose 
concentration had dropped ≥10 mmol/l was 147.9 ± 14.4 minutes after 
insulin administration by jet injection, compared with 192.5 ± 13.6 minutes 
after insulin administration with a conventional pen (difference 44.6 minu-
tes [95%CI 4.3 to 84.8]; P=0.03). In two patients with type 1 and one patient 
with type 2 diabetes (mean BMI, 32.6 ± 2.8 kg/m2), the primary endpoint 
was not reached on the jet injection day. The maximal falls in plasma gluco-
se were 4.8, 8.6, and 9.6 mmol/l, with corresponding peak insulin levels of 
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Jet injector Conventional pen P-value
Pharmacodynamic endpoints
T-BG≥10, min 147.9 ± 14.4 (n=17a) 192.5 ± 13.6 (n=20a) 0.03
T-BG10, min 163.2 ± 17.3 (n=14a) 214.1 ± 16.0 (n=17a) 0.04
T-BG5, min 220.8 ± 21.5 (n=6a) 270.0 ± 17.3 (n=3a) 0.19
BG-AUC0-2h, 
mmol∙min∙l-1
2042 ± 37.2 2168 ± 26.1 0.01
BG-AUC0-6h, 
mmol∙min∙l-1
4226 ± 241.8 4539 ± 142.4 0.24
Rfall, mmol∙l-
1∙min-1
0.080 ± 0.005 0.064 ± 0.004 0.03
Pharmacokinetic endpoints
C-INSmax, mU/l 140.6 ± 24.4 101.7 ± 14.7 0.003
T-INSmax, min 40.5 ± 3.2 76.8 ± 7.7 <0.001
INSAUC, mU∙min∙l-1 14363 ± 2498 12390 ± 1858 0.06
T-INSAUC50%, min 107.1 ± 9.4 139.7 ± 5.9 0.003
Table 2 -  Pharmacodynamic and pharmacokinetic endpoints. a n represents the number 
of patients that reached the endpoint. T-BG≥10, the time in minutes until plasma glucose 
concentration had dropped by ≥10 mmol/l; T-BG5 (10), the time in minutes until plasma 
glucose values had dropped below 5 (10) mmol/l; BG-AUC0-2h (0-6h), the area under the 
time-glucose curve, reflecting post-injection hyperglycaemic burden, from 0 to 2 (6) hours 
after insulin injection; Rfall, the slope of the glucose fall, calculated from the time-glucose 
curve during the first 30-120 minutes of the test; C-INSmax, maximal insulin concentration; 
T-INSmax, the time in minutes to maximal insulin concentration; INSAUC, the area under the 
insulin concentration curve, reflecting total insulin absorption; T-INSAUC50%, time until 50% 
of insulin absorption.
63.1, 66.0 and 118.6 mU/l, respectively. Recalculation of the data (using 
a paired t test) after exclusion of these patients did not materially change 
the outcome (147.9 ± 14.4 versus 197.9 ± 15.0 minutes for jet injector and 
conventional pen, respectively, P=0.012). Similarly, when we calculated the 
time until all patients achieved the minimal measured fall in plasma glucose 
of 4.8 mmol/l, the jet injector still performed significantly faster than the 
conventional pen (80.8 ± 14.4 versus 92.5± 4.8 minutes, P=0.007). 
After one hour, glucose values had dropped by 4.4 ± 0.3 mmol/l after jet 
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injection and by 3.0 ± 0.2 mmol/l after conventional injection (P=0.001). The 
hyperglycaemic burden, as reflected by the area under the glucose concen-
tration curve (AUC) was significantly less for the jet injector during the first 
two hours after insulin administration (P=0.01; Figure 1A and Table 2), but 
did not differ for the remainder of the test. The times until plasma glucose 
values dropped below 10 and 5 mmol/l were also numerically shorter for 
the jet injector than for the conventional pen, but not statistically since the-
se endpoints were achieved in a subset of patients (Table 2). 
In subgroup analyses, a higher BMI was independently associated with gre-
ater time benefit of jet injection with respect to the primary endpoint (97.2 
± 19.2 vs. 3.1 ± 17.0 minutes for BMI above and below the median of 31.2 
kg/m2, respectively, P=0.007), but diabetes type was not (P=0.31). The use 
of soda drink prior to the experiments had no effect on this outcome (time 
benefit of jet injection 57.5 ± 31.9 minutes for soda-users compared with 
43.3±19.5 minutes for non-users, P=0.703), or on any of the other outco-
mes.  
PHARMACOKINETIC ENDPOINTS
Insulin values could be measured in all patients except for one patient, in 
whom the presence of insulin antibodies resulted in cross-reactivity with 
the analysis. The changes from baseline in plasma insulin levels for both 
devices are displayed in Figure 1B. Jet injection advanced the absorption of 
insulin compared to conventional injection, as reflected by a shorter time 
to peak insulin levels (40.5 ± 3.2 vs. 76.8 ± 7.7 min, P<0.001; Table 2) and 
approximately 50% higher peak insulin levels (140.6 ± 24.4 vs. 101.7 ± 14.7 
mU/l, P=0.003). Jet injection significantly advanced the time in minutes until 
50% of insulin absorption (by 32.6 minutes, P=0.003). Total insulin absorpti-
on, reflected by the area under the insulin-concentration curve, appeared to 
be greater after jet than after conventional injection (difference 1973 mU∙-
min∙l-1 [95%CI -229.2 to 4175.2], P=0.06; Table 2), yet this was probably the 
consequence of the slightly greater insulin dose injected by jet stream. In 
one of the three patients who did not reach the primary pharmacodynamic 
endpoint, insulin levels remained relatively low (INSAUC 958.1 mU∙min∙l-1; 
maximal drop in plasma glucose 4.8 mmol/l), suggesting insufficient insulin 
administration or absorption, whereas insulin levels were appropriately 
elevated in the other two cases (7049 and 8448 mU∙min∙l-1; maximal drop 
in plasma glucose 9.6 and 8.6 mmol/l). 
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Figure 1 - Changes in plasma glucose and insulin levels during the experiments.  Data are 
presented as  mean ± SE changes in plasma glucose levels (top) and plasma insulin levels 
(bottom) during the experiments, from baseline (moment of insulin administration) to six 
hours after insulin administration by jet injection (black circles) and conventional insulin pen 
(white squares).
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SAFETY AND EASE OF USE
In 7 experiments (18%), three with the jet injector and four with the con-
ventional pen, all in patients with type 1 diabetes, exogenous glucose was 
administered to prevent hypoglycaemia. There were no differences between 
the two devices in the time to the start of glucose administration (208 ± 8 
vs. 218 ± 40 minutes; P=0.84), or the amount of exogenous glucose adminis-
tered (14.3 ± 5.3 vs. 17.7 ± 8.2 g; P=0.77). Adverse effects reported during 
the experiments were mostly mild to moderate in nature, and associated 
with hyperglycaemia (thirst, polyuria and nausea), which resolved quickly 
after glucose levels decreased. One patient requiring glucose infusion deve-
loped phlebitis, which resolved without treatment within four weeks. The 
amount of pain or discomfort experienced with the jet injector or conven-
tional pen was rated 1.8 ± 0.4 and 1.2 ± 0.1 (P=0.38), respectively;  the (un)
ease of use was rated 2.7 ± 0.4 with jet and 1.6 ± 0.2 with conventional pen 
injection (P=0.49). Of the 20 patients included, 6 preferred the jet injector, 7 
preferred the conventional pen, and 7 did not have a preference  (P=0.95).
CONCLUSION
The present study shows in overweight or obese patients with type 1 or 
type 2 diabetes that administration of a rapid-acting insulin analogue by jet 
injection resulted in faster correction of hyperglycaemia, by approximately 
45 minutes, compared to administration with a conventional insulin pen. 
Insulin administration by jet injection also decreased the hyperglycaemic 
burden during the first two hours, without posing a greater risk of late 
hypoglycaemia. The two devices were rated equally, both with respect to 
discomfort as with respect to ease of use by the trial population, consisting 
of diabetes patients highly experienced with and unbiased towards contem-
porary insulin therapy. These findings suggest that insulin administration by 
jet injection provides an effective and user-friendly way to correct marked 
hyperglycaemia in patients with insulin-treated diabetes. 
The advantage of insulin administration by jet over that by conventional 
injection with respect to normalizing plasma glucose levels, duration of 
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hyperinsulinemia, and hyperglycaemic burden, is in line with our previous 
studies conducted both in healthy and in diabetic subjects (11-13), and 
with studies comparing jet injectors with needle syringes (3, 5-9). Indeed, in 
those studies, jet injection reduced both the time to peak insulin levels and 
to maximal insulin action as well as the duration of insulin action by approxi-
mately 30-45 minutes. Also in line with previous results is our observation 
that jet injection appeared most beneficial for patients with higher BMI, 
who consequently required more insulin, although the underlying mecha-
nism remains to be explained (13).  
Most guidelines recommend to measure plasma glucose one hour after 
administration of a corrective insulin dose for (marked) hyperglycaemia (17). 
However, the initial drop in plasma glucose concentration after conventional 
pen injection in our study was only 3 mmol/l (range, 1.1 to 4.6 mmol/l). A 
glycaemic response that is too small may tempt patients and health ca-
re-providers to repeat the insulin injection, which in turn increases the risk 
for late hypoglycaemia. Administration by the jet injector resulted in an 
almost fifty percent greater glucose fall. Other benefits of advanced correc-
tion of marked hyperglycaemia include less time spent in hyperglycaemia 
and the resultant potential to avert metabolic complications such as diabetic 
ketoacidosis and hyperosmolar hyperglycaemic state, potentially fatal con-
ditions that often necessitate hospital admission (1, 18). Finally, apart from 
its use in an out-patient setting, the jet injector may also prove useful in the 
hospital, where hyperglycaemia is frequently encountered and difficult to 
manage (17).  
In the present trial, we used an adjusted formula based on the individual 
insulin sensitivity factor to calculate insulin doses adjusted to individual 
patient needs. This contrasts with the more or less fixed sliding-scale algo-
rithms used in daily practice and in most other trials conducted in patients 
with diabetes experiencing hyperglycaemia (14, 19, 20). This easy-to-use 
calculation turned out to perform well, leading to adequate correction of 
marked hyperglycaemia in 93% of cases.  
Our study has strengths and weaknesses. A strength of our trial is that it 
reflects real-world practice, in that hyperglycaemia was reached without 
parenteral interventions, much the same as in daily life. Inherently to this 
design lies a weakness of the study, in that it allowed glucose values to 
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differ slightly between the two test days. However, the difference in base-
line glucose values was small (<10% from the mean value) and unlikely to 
have had a meaningful impact on any of the outcomes. To further represent 
real-world practice, the device was operated by the patient when feasible. 
Although the lack of a double-blind design may be criticized, it is hard to 
imagine how this would change the results, since the insulin-induced fall 
in glucose is difficult to manipulate. We made sure that all conditions were 
exactly the same on both testing days, so that any potential modulation by 
the participant or research staff was kept to an absolute minimum. Therefo-
re, the absence of a placebo-injection might only have had minimal, if any, 
influence on the results. 
 
In two participants, insulin administration by the jet injector resulted in 
a ‘wet-injection’, for which we had to reschedule the test day. In another 
participant, even though we did not observe a wet injection, hyperglycae-
mia was inadequately corrected due to low plasma insulin levels, suggesting 
insufficient insulin absorption from the subcutaneous tissue. Such errors 
are obviously undesirable for a product that needs to be administrated on 
a daily basis (21), and underscore that handling this device may be cum-
bersome. Previous research showed that administration of an entire insulin 
dose by jet injection can be achieved in almost all circumstances, when 
sufficient training is provided (22). Nevertheless, the inter-individual varia-
bility in insulin action observed in the present study appeared not different 
for conventional and jet injection. In line with our previous research, insulin 
administration by this jet injector was well tolerated and not dissimilar from 
conventional pens (12). Finally, it should be acknowledged that the phar-
macological profile of insulin injected by jet stream and the tolerability of 
the device are specific to the jet injector used in this study; our data cannot 
simply be extrapolated to other jet injectors (23). 
In conclusion, aspart insulin administered by jet injection results in a more 
rapid and equally safe correction of marked incidental hyperglycaemia as 
compared with administration by a conventional insulin pen, especially 
in patients with a higher BMI. These effects may be clinically relevant for 
patients with diabetes treated with rapid-acting insulin. Further research is 
needed to elucidate the applicability of jet injection in daily practice.
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ABSTRACT
It is usually recommended to check plasma glucose one hour after insulin 
injection for the correction of incidental marked hyperglycaemia in people 
with insulin-requiring diabetes, even when standard sliding scale regimens 
unadjusted to individual needs are used. We evaluated the clinical relevance 
of this recommendation when the correctional dose of insulin was individu-
alized. 
We analyzed data from a randomized, controlled, cross-over trial on the 
correction of a plasma glucose value of 20.4±0.5 mmol/l with a widely-used 
commercial insulin pen in people with insulin-treated diabetes. Aspart 
insulin was injected subcutaneously in a dose determined by the following 
calculation: ([measured glucose value in mmol/l–6[=target glucose va-
lue]÷[100÷total daily insulin dose])•1.5). Plasma glucose levels were measu-
red for 6 hours thereafter. 
10 people with type 1 diabetes and 10 with type 2 diabetes were enrolled. 
Glucose values dropped 14.2±0.6 mmol/l to a nadir of 6.4±0.4 mmol/l after 
injection of 20.3±2.4 insulin units. Glucose values fell by only 3.2±0.5mmol/l 
one hour after injection and by 7.3±0.7mmol/l after two hours. In 60% of 
patients, plasma glucose values fell <3 mmol/l in the first hour. The formula 
led to optimal correction on 17 occasions (85%), but overestimated insulin 
needs (requiring exogenous glucose to prevent hypoglycaemia) on 3 (15.0%) 
occasions.  
Despite high individualized insulin doses, which were sufficient to optimally 
correct marked hyperglycaemia in most participants, the initial glucose-lo-
wering response was modest. The clinical significance of checking glucose 
values one hour after insulin injection is limited, even when ‘rapid-acting’ 
insulin is used.
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INTRODUCTION
In non-critically ill in-patients with diabetes, the American Diabetes Associ-
ation (ADA) recommends that glucose values should be below 10 mmol/l, 
and that treatment should be initiated once this level is exceeded (1). Despi-
te these recommendations, glucose levels far exceeding this threshold are 
frequently encountered in daily practice (2). In these patients, hyperglycae-
mia is associated with increased risks of cardiac, neurologic and infectious 
complications, higher mortality and increased length of hospital stay (3-5). 
The hospital setting creates a particularly high risk of the development of 
marked hyperglycaemia due to co-existing illness, use of drugs that increase 
blood glucose levels (e.g. glucocorticoids), the need to stop glucose-lowe-
ring drugs (e.g. metformin), or the use of tube or parenteral feeding or diets 
otherwise rich in carbohydrates. 
Although basal-bolus insulin regimens are preferred to optimize glucose 
control in hospitalized patients with diabetes (1), standard sliding scale regi-
mens are still widely applied for the correction of marked hyperglycaemia. 
These regimens are usually not or only barely adjusted to individual needs 
(6) and tend to underestimate the required correctional insulin dose. In 
our experience, many in-patient protocols recommend to repeat a glucose 
measurement 1 hour after insulin injection, even though it takes at least 90 
minutes for the maximal glucose lowering effect to set in, even with ra-
pid-acting insulin analogues (7). Re-applying the sliding scale regimen may 
then result in injecting the same insulin dose, which increases the risk for 
late hypoglycaemia and considerable glucose fluctuations (8, 9). 
Recently, we compared two insulin injection pens for the correction of 
marked hyperglycaemia in overweight people with type 1 or insulin-trea-
ted type 2 diabetes. In this study, we calculated the correctional dose of 
rapid-acting insulin for each individual on the basis of the insulin sensiti-
vity factor, multiplied by 1.5 to compensate for hyperglycaemia-induced 
glucose-toxicity (10). In this paper, we evaluated the data on the rate of the 
decline in plasma glucose when this easy-to-use algorithm was applied to 
correct marked hyperglycaemia with a widely-used commercially availa-
ble insulin pen. The data were used to assess the significance of retesting 
glucose measurements 1 hour after insulin administration and the overall 
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RESEARCH DESIGN AND METHODS
This was an analysis of data from a randomized, controlled, cross-over study 
that was originally developed to compare the pharmacokinetic and -dyna-
mic properties of a jet injector insulin pen (InsujetTM; European Pharma 
Group bv, Schiphol-Rijk, the Netherlands) and a conventional pen (FlexPen®, 
Novo Nordisk, Bagsværd, Denmark) for the correction of marked hyper-
glycaemia. For the present analysis, we only used data from the Flexpen. 
The study was approved by the institutional review board of the Radboud 
university medical center and all participants provided written informed 
consent. The procedures followed were in accordance with the Declaration 
of Helsinki.
EXPERIMENTAL STUDY DESIGN
The details of enrollment criteria and study procedures have been published 
elsewhere (10). Briefly, the study enrolled adults with type 1 or type 2 dia-
betes, aged 18-75 years, with a BMI of 25-40 kg/m2. All participants were 
on a basal-bolus insulin regimen (i.e. with multiple injections at least four 
times daily, or with a subcutaneous insulin pump) with a total daily insulin 
dose (TDID) of at least 34 and no more than 200 units. Participants were te-
sted in fasting condition. They were instructed to reduce their insulin doses 
one day before the experiments, in order to reach hyperglycaemia. On the 
experimental day, a catheter was inserted in retrograde fashion in a dorsal 
hand vein for blood sampling and frequent glucose measurements (Biosen 
C-line GP+, EKF-diagnostic GmbH, Barleben, Germany). After having ob-
tained a plasma glucose level of 18-23 mmol/l, insulin aspart (NovoRapid®, 
Novo Nordisk, Bagsvaerd, Denmark) was administered by a conventional 
insulin pen (Flexpen®). Thereafter, plasma glucose levels were measured 
at 5-minute intervals during the first three hours, and at 10-minute inter-
vals for the next three hours. If plasma glucose values dropped below 4.8 
mmol/l, a second intravenous catheter was inserted in the opposite arm 
for the administration of glucose 20%. After six hours, the experiment was 
terminated, and the participant was given a meal. 
performance of the algorithm.
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The administered insulin dose was calculated by the following formula:
1.5 x ([actual glucose]-[glucose target]) ÷ ISF,   (1)
in which [actual glucose] is the glucose level at the start of the experiment; 
[glucose target]  the glucose objective, set at 6 mmol/l in our study; and 
ISF the insulin sensitivity factor (11), calculated by dividing 100 by the 
total daily insulin dose (TDID). The multiplication factor of 1.5 was used to 
compensate for possible hyperglycaemia-induced insulin resistance (gluco-
se toxicity) (12, 13), and to ensure that sufficient insulin was administered. 
Thus, for a participant with a TDID of 50 units and an initial plasma glucose 
level of 22 mmol/l, the number of units to be administered was calculated 
as: 1.5 x (22-6) ÷ (100÷50) = 12. The calculated insulin dose was rounded up, 
to a maximum of 40 units.  
STATISTICAL ANALYSES
Endpoints were derived from the time-action glucose profiles. These 
included the accuracy of the formula, as determined by the proportion of 
experiments in which a plasma glucose value between 4.8-10 mmol/l was 
achieved,  the mean maximal drop in plasma glucose levels after insulin 
injection, the time in minutes until plasma glucose levels dropped below 10 
mmol/l, and the amount of exogenous glucose needed to prevent hypogly-
caemia. Subgroup analyses were performed according to diabetes type, sex, 
and the accuracy of predicting insulin needs by the formula. For the latter, 
we distinguished the subgroup in whom the formula performed optimal 
(defined as achieved plasma glucose between 4.8-10 mmol/l) from those in 
whom the formula overestimated insulin needs (achieved plasma glucose 
value <4.8 mmol/l, requiring exogenous glucose) or underestimated insulin 
needs (achieved plasma glucose level >10 mmol/l). Glucose values for sub-
groups were tested for normal distribution and compared with an unpaired 
T-test or Wilcoxon signed rank test. Correlation coefficients were calculated 
by using Pearson’s correlation test. Percentages were compared with a 
Chi-square test. Statistical analyses were performed by SPSS 20.0 (IBM SPSS 
Statistics for Windows, Version 20.0, IBM Corp, Armonk, NY USA). A P-value 
of <0.05 was considered significant.
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Type 1 diabetes Type 2 diabetes
Mean age, years 48.0 ± 12.3 58.7 ± 6.8
Sex, men:women 7 : 3 7 : 3
Duration of diabetes, years 28.7 ± 11.9 17.8 ± 8.2
Treatment regimen
     Pump therapy 6 2
     MDI 4 8
TDID, units/day, median (range) 57 (34-109) 136 (36-200)
HbA1c 
     mmol/mol 68.0 ± 11.7 71.8 ±12.4
     % 8.4 ± 1.1 8.7 ± 1.1
BMI, Kg/m2 29.7 ±3.7 34.7 ± 4.3
Initial plasma glucose, mmol/l 20.8 ± 2.7 21.8 ± 2.7
Insulin dose administered, units 14.3 ± 5.9 29.1 ± 11.5
Table 1 - Baseline characteristics. Data are expressed as number, median (range) or mean ± 
SD. Abbreviations: BMI denotes body mass index; TDID denotes total daily insulin dose; MDI 
denotes multiple daily injections.
The first 5-10 minutes after insulin injection, plasma glucose levels slightly 
increased to 20.6 ± 0.5 mmol/l. Subsequently, glucose levels dropped by 3.2 
± 0.5 mmol/l and 7.3 ± 0.7 mmol/l during the first and second hour after 
insulin injection, respectively (Fig. 1). In 12 patients (60%), plasma glucose 
values fell <3 mmol/l in the first hour. On average, plasma glucose levels fell 
below 10 mmol/l after 201.3 ± 13.9 minutes, whereas it took 323.5 ± 12.1 
minutes before the glucose nadir of 6.4 ± 0.4 mmol/l was reached (Fig. 1). 
Twenty participants, 10 with type 1 diabetes and 10 with type 2 diabetes, 
were enrolled. Baseline characteristics are presented in Table 1. The mean 
plasma glucose value before insulin injection was 20.4 ± 0.5 mmol/l, for 
which 20.3 ± 2.4 units of insulin were injected. In 1 case, the maximal insulin 
dose of 40 units was administered, which was slightly below the calculated 
dose (42 units). 
RESULTS
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On 17 (85%) occasions the formula well predicted insulin needs. On three 
(15%) occasions (all with type 1 diabetes), the formula overestimated insu-
lin needs, thus requiring administration of exogenous glucose (14.3 ± 5.3 g, 
range 4-22 g) after 207.7+/-7.9 minutes to avoid hypoglycaemia. Underesti-
mation of insulin needs did not occur. 
One- and 2-hour plasma glucose values were significantly lower on occa-
sions where the formula overestimated insulin needs, as compared with 
occasions in which the formula predicted well (1-hour: 15.2 ± 0.6 vs. 17.8 ± 
0.5 mmol/l; 2-hour: 8.9 ± 2.1 vs. 14.1 ± 0.6 mmol/l; both P<0.05, Fig. 2). The 
rate of initial glucose decline (as measured by the slope during the first 2 
hours) and the glucose nadir were associated with estimated insulin sensi-
tivity (R=0.55, P=0.013 and R=-0.46, P=0.048). The  algorithm tended to be 
more accurate for patients with type 2 diabetes (P=0.060), but there was no 
significant difference in accuracy between males and females (P=0.89). 
Figure 1 - Plasma glucose values after insulin injection for participants with type 1 diabetes 
(black circles) or type 2 diabetes (white squares). 
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Figure 2 - Plasma glucose values at t=120 minutes (A) and t=180 minutes (B) after insulin 
injection, according to the accuracy of the algorithm for achieving target glucose values. Fop-
timal: optimal prediction of insulin needs; Foverestimation: overestimation of insulin needs. 
*P<0.05
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CONCLUSION
This analysis showed that the individualized dose we calculated to correct 
marked hyperglycaemia was relatively high, yet resulted in near-normaliza-
tion of plasma glucose values in 85% of patients with diabetes. Surprisingly, 
despite the high insulin dose, the fall in plasma glucose one hour after 
insulin injection was fairly modest, even in patients in whom the algorithm 
overestimated insulin needs. Although it is common practice to evaluate 
glucose levels at this time point to guide further treatment decisions, our 
data suggest that it would be better to wait another hour.   
Our data underscore the importance of patience. The duration of absorbing 
insulin from the subcutaneous compartment into the circulation and its 
subsequent glucose-lowering action has been estimated at 30-45 minu-
tes (7, 14). Indeed, glucose values fell only modestly in the first hour and 
could even increase within the first 10 minutes. We therefore recommend 
to repeat glucose measurements not earlier than 120 minutes after insulin 
administration. Hypoglycaemia did not occur before this time point, alt-
hough our data suggest that it would be wise to ingest some carbohydrates 
when glucose levels have fallen below 12 mmol/l at 120 minutes to prevent 
such an event (Fig. 2). We would also recommend to wait at least another 
hour before considering a repeated insulin injection because of insufficient 
glucose decline. While most of the fall in plasma glucose occurred in the 
second hour, the glucose levels achieved after two hours did not discrimina-
te between participants who reached the glycaemic target range and those 
who did not (Fig. 2a). This only occurred after the third hour, when over 
75% of insulin action was completed, although there was still substantial 
overlap between these two groups (Fig. 2b). It should be noted that the 
algorithm presented here cannot be used to calculate the amount of extra 
insulin necessary to achieve the glycaemic target when the first injection 
was insufficient. 
Marked elevations in plasma glucose levels are fairly common among peop-
le with insulin-treated diabetes. However, most guidelines provide very little 
assistance on how to manage marked hyperglycaemia or fail to mention the 
issue at all (15). Sufficient insulin administration is not only important to 
limit the hyperglycaemic period, but also to dissuade patients from repea-
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ting insulin injection(s) when glucose levels fail to respond, which ultimately 
increases the risk for hypoglycaemia. Standard sliding scale regimens remain 
largely devoid of individualization, ignore glucose toxicity and are therefore 
prone to considerable underestimations of the required dose for adequa-
te correction, particularly in type 2 diabetes. Indeed, we used an average 
insulin dose of more than 20 units, whereas guidelines advocate a maximal 
dose of 18 units of insulin only for severely insulin-resistant patients with 
a glucose level exceeding 22 mmol/l (16). Published algorithms to correct 
hyperglycaemia in hospitalized patients are similarly restrictive (17). Consi-
dering both the effect of glucose toxicity and individualized insulin require-
ments, we developed an algorithm resulting in correction insulin doses that 
were considerably higher than usually advocated. Yet we showed that doses 
up to 40 units were safe for achieving normoglycaemia in the vast majority 
of participants. 
Our study has limitations. First, the study population consisted of over-
weight participants with diabetes who were otherwise healthy. Extrapola-
tion to a normal-weight diabetes population should be done with caution. 
Second, hyperglycaemia was induced by insulin depletion. We therefore 
cannot vouch for the accuracy of the algorithm in settings in which other 
factors, such as the use of prednisone, overeating, infections, and stress 
contribute to hyperglycaemia. Nevertheless, the algorithm is unlikely to 
overestimate insulin requirements in these conditions and may still provide 
guidance in determining the insulin dose needed to overcome hyperglycae-
mia. Third, we only tested the algorithm in participants with marked hyper-
glycaemia (arbitrarily set at a plasma glucose level of >18 mmol/l) that had 
not yet progressed to hyperosmolar disruption or ketoacidosis. Therefore 
we do not know whether the algorithm is also appropriate for higher or 
lower levels of hyperglycaemia. Fourth, the algorithm tended to overestima-
te insulin needs in insulin-sensitive patients with type 1 diabetes. Although 
exogenous glucose was not required in the first two hours,  it may be better 
to use a lower correction factor than 1.5 or not use the factor at all in these 
patients. Finally, we did not compare the algorithm to that of routine care 
for hyperglycaemic excursions in the hospital, so that we cannot determine 
the exact differences between the two methods. 
In conclusion, our observations suggest that it takes long to correct marked 
hyperglycaemia, despite the relatively high dose of insulin used in this study. 
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Thus, it would be advisable to wait two hours rather than one before repea-
ting the glucose measurement and three hours before considering another 
insulin injection. Our algorithm, which can be easily applied in daily clinical 
practice, may provide some guidance in calculating insulin doses needed 
to correct marked hyperglycaemia in persons with insulin-treated diabetes. 
Further studies are needed to reveal the predictive value of this formula in 
different settings and in larger populations.
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SUMMARY AND CONCLUSIONS
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SUMMARY
Optimal insulin therapy for patients with type 1 diabetes or type 2 diabetes 
with severe insulin deficiency consists of a basal-bolus regimen, in order 
to mimic the endogenous insulin profile as closely as possible. Although 
modern rapid-acting insulin analogues, the current standard ‘bolus’ compo-
nent, have a faster onset of action than regular human insulin, their phar-
macologic time-action profile is still substantially slower than that of endo-
genous insulin. As a consequence, both early postprandial hyperglycaemia 
and (late postprandial) hypoglycaemia remain frequent complications of 
insulin therapy in people with diabetes.
Prandial insulin administration by a jet injection is a currently available 
approach to accelerate insulin absorption. When insulin is injected by jet 
stream, it is dispersed over a larger area in the subcutaneous matrix than 
when insulin is conventionally administered by a syringe. Therefore, insulin 
is absorbed more rapidly into the circulation than insulin administered by 
conventional pen or needle-and-syringe. A more rapid rise and fall in insulin 
levels could translate into improved glucose control. The present thesis des-
cribes the results of studies regarding the pharmacologic profile of rapid-ac-
ting insulin analogues administered with a modern jet injector. 
In the first study, (described in chapter 2), we compared the pharmacologic 
profile of jet-injection to conventional insulin pen administration for the ra-
pid-acting insulin analogue insulin aspart. The study had a randomized dou-
ble-blind double-dummy cross-over design, in which the ‘dummy’ consisted 
of injection of Testmedium, which is identical to the insulin formulation ex-
cept for the insulin itself. In agreement with our hypothesis, we found that 
insulin was absorbed twice as fast when it was administered by jet injection. 
This translated into equally shorter time until maximal glucose-lowering 
insulin effect. In addition, the total duration of hyperinsulinaemia was redu-
ced by 30-40 minutes, which resulted in a similarly shorter duration of the 
total glucose-lowering effect. This improved pharmacological profile could 
lead to a better postprandial control of glucose values.  
Using a similar study design, we then tested whether jet injected (more 
affordable) regular human insulin administration could achieve the same 
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beneficial pharmacokinetic properties comparable to conventionally admi-
nistered rapid-acting insulin analogue.  Indeed, as described in chapter 3, 
the time-action profiles of jet injected regular human insulin and conven-
tionally administered insulin aspart were largely superimposable. Human 
insulin administered by jet injector had even a slightly faster onset of action 
than the rapid-acting insulin analogue administered by conventional pen. It 
is likely that the clinical benefits of rapid-acting insulin analogues (such as 
skipping the 30-minute interval between insulin administration and meal 
consumption and treatment flexibility) also apply to regular human insulin 
when injected by jet stream. Thus, using a jet injector to inject regular hu-
man insulin could be an alternative to the use of rapid-acting insulin analo-
gues when the latter are not tolerated, too costly or not available. 
The glucose-lowering effect of repeated administration of insulin either 
by conventional pen or by needle-and-syringe can vary within one subject 
(intra-individual variability) by as much as 20%. In chapter 4, we report the 
inter- and intra-individual variability of aspart insulin injected by jet stream 
in thirty healthy volunteers. First, the study confirmed the findings reported 
in chapter 2, in that we found again that the times until peak insulin levels 
and until the maximal glucose lowering effect were considerably shorter 
when insulin was administered by jet injection instead of conventional pen. 
The intra-individual variability of the (time until) maximal glucose-lowe-
ring effect of insulin was considerable and varied between 6 and 35%. The 
pharmacodynamic variability was roughly comparable after jet injection and 
conventional administration. This study therefore emphasizes that a certain 
variability in  glucose-lowering effect after insulin administration seems 
unavoidable, regardless of the method of insulin administration. 
It has been reported that the absorption and subsequent glucose-lowering 
effect of rapid-acting insulin is substantially slower in obese people with 
type 2 diabetes than in healthy lean subjects without diabetes. To assess 
the impact of body weight on our observations, we analyzed the data of the 
study described in chapter 2 post-hoc in subgroups defined by body-mass 
index (BMI). This analysis, reported in chapter 5, confirmed that the insu-
lin absorption rate is considerably determined by BMI when insulin was 
injected by the conventional pen: the higher the BMI, the slower the insulin 
absorption and subsequent glucose-lowering effect. However, no such mo-
difying effect was observed when the insulin was injected by the jet injector. 
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Thus, although jet injection did benefit all subjects, this analysis suggests 
that subjects with a higher BMI benefit more from jet-injected insulin than 
those with a lower BMI. A possible explanation for the greater advantage 
of jet injection in participants with a higher BMI could be the higher insulin 
dose. The drop-like dispersion pattern of conventional insulin administration 
determines that the higher the insulin dose, the lower the ratio between 
the absorption surface and the insulin volume, thus prolonging the time of 
absorption. Since jet injected insulin has a spray-like dispersion pattern, the 
surface area is not only larger than after conventional administration, but 
probably increases in sync with increasing insulin doses, so that the ab-
sorption time does not change. 
Following our demonstration of faster insulin absorption and action after 
jet injection, we hypothesized that this could lead to a reduction of post-
prandial hyperglycaemic burden in people with diabetes. We investigated 
this by comparing glucose excursions after a standardized carbohydrate rich 
meal with jet injected and conventionally administered insulin in people 
with type 1 or insulin-treated type 2 diabetes. As described in chapter 6, 
insulin was absorbed almost twice as rapid after administration by a jet 
injector compared to a conventional pen, which decreased postprandial 
hyperglycaemia particularly during the first hour. Although the benefit of jet 
injection seemed limited, it could be potentially beneficial in patients with 
a disproportionate rise in postprandial glucose, since a postprandial rise in 
glucose contributes significantly to overall glycaemic control. 
A faster insulin absorption after jet injection could also be beneficial in 
correcting marked hyperglycaemia in patients with diabetes. In the study 
described in chapter 7, patients were instructed to reduce their insulin 
use to such an extent that glucose values increased to 18-21 mmol/l the 
next morning. Each patient received an individualized correction dose of 
rapid-acting insulin with either a jet injector or a conventional pen. On 
average, it took 3-4 hours before glucose levels approached normoglycae-
mia, but hyperglycaemia correction was 45 minutes faster when using a 
jet instead of a pen. Jet injection also reduced the hyperglycaemic burden 
during the first 2 hours, without increasing the risk of hypoglycaemia. Faster 
correction of hyperglycaemia is important for reducing the risk of metabolic 
derangements, including ketoacidosis. In addition, observing a more imme-
diate effect on plasma glucose may dissuade patients from repeating the 
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corrective insulin administration. Our findings may not only provide useful 
in an out-patient setting, but also for hospitalized patients, where hypergly-
caemia is frequently seen and difficult to manage. 
Current guidelines for hyperglycaemia correction often advocate standard 
sliding-scale regimens that do not take into account the individual insulin 
sensitivity. The dose recommendations in these regimens are usually at the 
lower end to avoid hypoglycaemia. As a consequence, the dose is often too 
low to timely correct marked hyperglycaemia, particularly in patients with 
type 2 diabetes. This may tempt the patient or caregiver to repeat insulin 
administration (insulin stacking), inadvertently increasing the risk of hypog-
lycaemia. For the study described in chapter 7, we therefore used correcti-
on doses that were tailored to the estimated individual insulin sensitivity. 
In chapter 8, we more closely describe the glucose fall time-course in res-
ponse to these individualized insulin doses. This analysis demonstrated that 
even with adequate insulin dosing (>85% of patients achieved the target 
glucose value of <10 mmol/l), the fall in plasma glucose level over the initial  
hours remained quite modest. To prevent repeated insulin injections with 
a concomitant hypoglycaemia risk, we advise to repeat a glucose measure 
not after one (as is commonly recommended), but after a minimum of two 
hours. Our analysis also support the use of higher insulin doses than cur-
rently recommended to adequately correct marked hyperglycaemia. The 
algorithm provides guidance in calculating insulin doses needed to correct  
hyperglycaemia for the individual patient, but it needs verification in pa-
tients with a normal BMI, in hospital settings and for mild hyperglycaemia. 
In previous studies, performed with older jet injectors, participants some-
times reported pain or developed hematomas after jet injection. Despite 
the large number of jet injections we administered in our studies (over 200 
jet injections), none of our participants experienced bruises or pain. Pa-
tients rated jet injection similarly (un)comfortable as conventional injec-
tion and, when asked, had equal preference rates for the jet injector or 
the conventional pen. However, we did experience a few “wet” injections, 
administrations where insulin does not penetrate the skin but remains on 
the surface, despite the current jet injector’s built-in lock/release system. 
Further technological improvements are obviously required for more wi-
despread use in daily practice.
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In this thesis, we compared the pharmacokinetic and pharmacodynamic 
profile of insulin administered by jet injection with conventional insulin pen 
administration. We showed that jet injection consistently accelerates sub-
cutaneous insulin absorption. This accelerated insulin absorption leads to a 
more rapid and shorter duration of glucose-lowering effect, a reduction in 
hyperglycaemic burden in the first hours after a meal and faster correction 
of marked hyperglycaemia. These findings account both for healthy indivi-
duals and patients with diabetes, and for the rapid-acting insulin analogue 
insulin aspart as well as for regular human insulin. In fact, using a jet injector 
for regular insulin administration achieved the same pharmacological bene-
fits as that of a rapid-acting insulin analogue. The acceleration in insulin ab-
sorption and action after jet injection appears more pronounced in people 
with a higher BMI. The intra-individual variability in insulin absorption and 
insulin action was significant but quite similar for a jet injector as compared 
to conventional devices. Since no differences seem to exist with respect to 
user experience, preference and patient safety, jet injection could be consi-
dered as an alternative to conventional pen for insulin administration.
Although (rapid-acting) insulin administration by jet injection is associated 
with clear pharmacological benefits, the use of jet injectors has also limi-
tations. First, preparing the jet injector for use may take longer than the 
preparation of a conventional pen. Furthermore, filling the jet with insulin 
needs to be done manually, which makes the device prone to errors and 
compromises ease of use. A reduction in the number of steps that are 
necessary to prepare the jet injector for insulin administration could make 
the device more user-friendly, diminish the number of errors and improve 
device acceptation by both patients and care-providers. If the device could 
contain an prefilled insulin cartridge (just like conventional insulin pens 
have) instead of having to extract the exact number of insulin units before 
each injection, an important error-sensitive step in preparation could be 
eliminated. Second, jet injectors may be more expensive than regular insulin 
pens and reimbursement policies may differ from one insurance company to 
the other. 
Since jet injection controls postprandial glucose levels better than conven-
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tional insulin administration, and insulin absorption after jet injection does 
not seem to be influenced by BMI, jet injection would probably be most 
beneficial in obese patients or in patients with inappropriately elevated 
postprandial glucose levels. Since jet injection corrects marked hypergly-
caemia faster than conventional pen administration, jet injection could aid 
in situations where marked hyperglycaemia is commonly seen and rapid 
correction is desirable. These situations occur for example at hospital wards, 
where glucose levels may derange in patients treated with prednisone or 
with (par-) enteral feeding, or in emergency rooms, where patients are pre-
sented for hyperglycaemia. 
While our studies demonstrate an improved pharmacological profile when 
using jet injection for insulin administration, we have not yet investigated 
whether this translates into better overall glycaemic control and a redu-
ced risk of hypoglycaemia. Future research should therefore be directed 
towards long-term - preferably controlled - studies, in which patients are 
treated by jet injection for a substantial amount of time. In addition, more 
research should be directed towards specific patient categories, for example 
obese patients with high insulin needs who appear to derive particularly 
high benefit from jet injection. Such studies should elucidate the effect of 
rapid-acting insulin analogues administered by jet injection on glycaemic 
control. Meanwhile, the studies performed in this thesis show that jet-injec-
ted rapid-acting insulin analogues may have advantages in specific clinical 
situations, such as (marked) hyperglycaemia in hospitalized patients with 
diabetes. 
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NEDERLANDSE SAMENVATTING
Diabetes (oftewel suikerziekte) is een heterogene aandoening die gekarak-
teriseerd wordt door een chronische verhoging van de bloedsuikerspiegels 
(ook wel glucosespiegels genoemd). Deze verhoging wordt veroorzaakt door 
een absoluut of relatief tekort aan insuline, een hormoon gemaakt door 
bepaalde cellen in de alvleesklier. Insuline zorgt ervoor dat de lever minder 
glucose produceert en dat glucose wordt opgenomen in onder meer spier- 
en vetcellen. Hierdoor blijft de bloedglucosespiegel binnen nauwe grenzen. 
Patiënten met diabetes produceren onvoldoende (of in het geheel geen) in-
suline waardoor hun glucosespiegels stijgen Dit is gevaarlijk, omdat langdu-
rig verhoogde bloedglucosespiegels kunnen leiden tot blindheid, nierfalen, 
zenuwaandoeningen en hart- en vaatziekten. Voor patiënten met diabetes 
is het daarom van groot belang de bloedglucosespiegels zo goed mogelijk te 
reguleren om deze complicaties te voorkomen. Intensieve behandeling met 
insuline vermindert de blootstelling aan hoge glucosespiegels , waardoor 
het risico op het ontwikkelen van aan diabetes gerelateerde complicaties 
daalt.
Het aantal patiënten met diabetes is wereldwijd de afgelopen jaren sterk ge-
stegen. Dit komt onder andere door een toename van de totale wereldbe-
volking, een toename van de levensverwachting van patiënten met diabetes 
en een toename van het aantal mensen met overgewicht. Daarnaast wordt 
er beter en eerder gescreend op diabetes bij risicogroepen. De verwachting 
is dat het aantal patiënten met diabetes in Nederland in 2025 gestegen zal 
zijn tot 1,3 miljoen mensen, oftewel 8% van de totale bevolking. 
Er zijn grofweg 2 typen diabetes te onderscheiden. Type 1 diabetes is een 
auto-immuun ziekte, dat wil zeggen dat het eigen afweersysteem de insu-
line-producerende cellen in de alvleesklier kapot maakt. Hierdoor ontstaat 
een absoluut tekort aan insuline. Deze patiënten moeten worden behandeld 
met insuline. Bij patiënten met type 2 diabetes is er sprake van een vermin-
derde gevoeligheid voor insuline in combinatie met een relatief tekort aan 
insuline. De verminderde gevoeligheid voor insuline, die ook wel insuline-
resistentie wordt genoemd, betekent dat de cellen in lever, spieren en vet 
minder goed op insuline reageren. De insulineresistentie is gerelateerd aan 
overgewicht, weinig lichaamsbeweging en daarnaast ook genetische fac-
toren. Het tekort aan insuline bij type 2 diabetes wordt relatief genoemd, 
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omdat aanvankelijk de insulineproductie juist stijgt en diabetes pas ontstaat 
als er niet meer aan de toegenomen vraag aan insuline kan worden voldaan. 
De behandeling bestaat in eerste instantie uit een dieet, meer bewegen en 
eventueel tabletten om de gevoeligheid voor of de productie van insuline te 
stimuleren. Type 2 diabetes is echter een progressieve ziekte, dat wil zeggen 
dat de cellen in de alvleesklier langzaam steeds minder insuline gaan produ-
ceren. Uiteindelijk ontstaat er bij veel van deze patiënten ook een absoluut 
tekort aan insuline en zullen zij behandeld moeten worden met insuline. 
 
In 1922 is het voor het eerst gelukt insuline uit de alvleesklier te verkrijgen 
voor toediening aan mensen. Vanaf dat moment konden patiënten met 
diabetes met insuline worden behandeld. Insuline moet subcutaan wor-
den geïnjecteerd, omdat het bij orale toediening door het maagzuur wordt 
afgebroken. Sinds de jaren 20 van de vorige eeuw is er veel vooruitgang 
geboekt. Insuline wordt tegenwoordig met zeer fijne naalden toegediend 
en kan kunstmatig worden nagemaakt, waardoor het identiek is aan het 
hormoon dat normaliter in het menselijk lichaam zelf wordt gemaakt. Des-
ondanks is de glucoseregulatie verre van optimaal bij de overgrote meer-
derheid van patiënten met type 1 of insulineafhankelijke type 2 diabetes. Bij 
mensen zonder diabetes wordt insuline in precies afgepaste hoeveelheden 
door de alvleesklier afgegeven om glucosestijgingen door bijvoorbeeld een 
maaltijd tegen te gaan. Het blijkt in de praktijk erg lastig om bij patiënten 
met diabetes met insuline-injecties de normale situatie na te bootsen. Als er 
te weinig insuline wordt gespoten steigt (de zogenaamde hypers) de gluco-
sespiegel verhoogd, terwijl een te hoge dosis insuline juist te lage bloed-
glucosespiegels (de zogenaamde hypo’s) kan veroorzaken. Bovendien is de 
opname van insuline die onderhuids wordt gespoten relatief traag. Na injec-
tie moet insuline eerst onderhuids worden afgebroken in kleinere gedeeltes 
voordat het kan worden opgenomen in de bloedbaan. Pas dan kan insuline 
de glucose verlagen. Omdat het een tijdje duurt voordat insuline werkt, 
stijgt de glucose na een maaltijd in eerste instantie vaak te sterk. Daarnaast 
verdwijnt de insuline relatief langzaam uit het onderhuids weefsel. Hierdoor 
kan een overschot aan insuline ontstaan, terwijl de glucosespiegel alweer 
is genormaliseerd. Dit insulineoverschot kan dan leidt dan juist tot te lage 
bloedsuikers. De trage werking van insuline veroorzaakt vaak schommelin-
gen tussen te hoge en te lage bloedglucosespiegels. Kunstmatig verbeterde 
insulines worden al wat sneller in de bloedbaan opgenomen, maar nog niet 
snel genoeg. Het blijft dus een substantieel probleem voor patiënten die 
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insuline gebruiken. 
Snellere opname van insuline zou de behandeling van patiënten met 
diabetes ten goede kunnen komen. Er zijn verschillende methoden in 
ontwikkeling om dit te bewerkstelligen, al zijn de meeste hiervan nog niet 
beschikbaar voor toepassing in de dagelijkse praktijk. Een methode die al 
wel beschikbaar is voor gebruik in patiënten is toediening van insuline met 
een jet injector. Dit is een naaldloze insulinepen die werkt op basis van hoge 
luchtdruk. Hiermee wordt de insuline met grote snelheid rechtstreeks door 
de huid heen gespoten. Het onderhuidse verdelingsvolume wordt hiermee 
groter, waardoor de insuline sneller kan worden opgenomen. Aanwijzingen 
hiervoor komen uit enkele oudere studies. Deze onderzoeken hadden niet 
altijd de juiste studie-opzet, testten soms te weinig patiënten en onderzoch-
ten type insulines die nu nauwelijks meer worden gebruikt. Tegenwoordig 
worden vooral speciaal ontwikkelde snelwerkende insulinepreparaten 
(zogenaamde snelwerkende insulineanalogen) gebruikt, met name rondom 
de maaltijden en voor het corrigeren van glucoseontregelingen. Onderzoek 
naar het gebruik van de jet injector met deze moderne insulines was niet 
eerder gedaan. In dit proefschrift hebben we daarom onderzocht of een jet 
injector beter is dan een normale insulinepen om deze insuline zo snel mo-
gelijk in de bloedbaan te krijgen en daarmee een goed alternatief kan zijn 
voor de standaardtoediening. 
In het eerste onderzoek, dat beschreven wordt in hoofdstuk 2, vergeleken 
we de jet injector met de gewone insulinepen bij gezonde vrijwilligers. Op 
twee afzonderlijke dagen kregen zij de snelwerkende insuline analoog as-
part toegediend met een jet injector of met een gewone pen. Onze hypo-
these werd bevestigd. Wij vonden dat de insuline twee keer zo snel werd 
opgenomen in de bloedbaan als het met een jet injector in plaats van met 
een gewone pen was toegediend. Dit vertaalde zich ook naar een sneller 
glucoseverlagend effect: het maximaal glucoseverlagende effect werd  2 
maal sneller bereikt met de jet injector ten opzichte van de gewone pen.
 
Diabetes komt over de hele wereld voor, voor het merendeel in armere 
landen. De snelwerkende insulineanalogen, die in het algemeen als beste in-
suline voor de maaltijd worden beschouwd, zijn helaas niet overal beschik-
baar en/of betaalbaar. Daarom besloten we te onderzoeken of de gunstige 
eigenschappen van insuline aspart (zoals snellere opname, snellere werking, 
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minder late glucosedalingen) misschien te bereiken zijn door de (goedko-
pere) humane insuline toe te dienen met een jet injector (hoofdstuk 3). We 
vonden dat het farmacologische profiel van humane insuline toegediend 
met de jet injector sterk leek op dat van insuline aspart toegediend met 
de gewone pen. Er waren slechts kleine verschillen in bijvoorbeeld de tijd 
tot maximale insulineconcentratie en tot het glucoseverlagende effect van 
insuline. Het farmacologische profiel van op deze wijze toegediend humaan 
insuline komt waarschijnlijk genoeg overeen met dat van snelwerkende 
insuline om dezelfde gunstige eigenschappen te hebben op de bloedgluco-
seregulatie.
In de eerste studie varieerde het glucoseverlagende effect van insuline be-
hoorlijk tussen de deelnemers. Uit oudere onderzoeken was ook al naar vo-
ren gekomen dat het effect van insuline binnen één individu behoorlijk kan 
verschillen. Dit geldt zowel voor toediening met een normale insulinepen 
als voor toediening met een spuit en naald, zoals dit in veel landen buiten 
Europa nog steeds gebruikelijk is. Voor zover wij wisten was er nog nooit 
onderzoek gedaan naar de variabiliteit van het glucoseverlagende effect van 
insuline aspart toegediend met een jet injector. We hebben daarom een 
pilot studie uitgevoerd, beschreven in hoofdstuk 4. Dit is een studie die met 
name kijkt naar de globale grootte en richting van het effect en minder naar 
de absolute verschillen. In dit onderzoek gaven we gezonde proefpersonen 
op twee afzonderlijke dagen insuline met ofwel een gewone insulinepen of 
met de jet injector. Alle proefpersonen ondergingen dus twee maal hetzelf-
de experiment. De verschillen tussen de 2 dagen werden gebruikt om de 
variabiliteit van insulinetoediening te berekenen en te vergelijken tussen de 
gewone pen en de jet injector. Allereerst vonden we opnieuw dat insuline 
toegediend met de jet injector het bloed sneller bereikte en dat dit leidde 
tot snellere glucoseverlaging dan insuline ingespoten met een gewone pen. 
Na het vergelijken van de twee apparaten vonden we wat kleine verschillen 
in de variabiliteit in insuline-opname. Deze zorgden echter niet voor meer 
variabiliteit in het glucoseverlagende effect. We concludeerden daarom dat 
de variabiliteit in insuline-opname en het glucoseverlagende effect voor 
beide apparaten weliswaar groot is, maar waarschijnlijk niet wezenlijk van 
elkaar verschilt. De resultaten benadrukken dat patiënten met diabetes er 
helaas niet van uit kunnen gaan dat het glucoseverlagende effect van insuli-
ne elke keer hetzelfde is, ongeacht de methode van insulinetoediening. 
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Bij normale insulinetoediening verloopt de opname en de werking van insu-
line trager bij dikke patiënten dan bij patiënten met een normaal gewicht. 
In het onderzoek dat we bij gezonde vrijwilligers uitvoerden (hoofdstuk 2)  
vonden we hetzelfde voor insulinetoediening met de gewone insulinepen: 
bij de wat zwaardere proefpersonen (vastgesteld aan de hand van de bo-
dy-mass index of BMI) werkte de insuline trager dan bij de lichtere proefper-
sonen. Bij de insulinetoediening met een jet injector vonden we dit verschil 
echter niet. Hoewel zowel zwaardere als lichtere proefpersonen voordeel 
hadden van de jet injector, was het voordeel van de eerste groep duidelijk 
groter. Deze analyse staat beschreven in hoofdstuk 5. 
De resultaten met betrekking tot de snellere opname en effect van insuline 
moesten vervolgens worden bevestigd bij patiënten met diabetes en in een 
meer natuurlijke situatie, zoals na een maaltijd. In de studie beschreven in 
hoofdstuk 6 onderzochten we bij patiënten met diabetes of insuline aspart 
toegediend met een jet injector de glucosepiek na een maaltijd inderdaad 
sneller kon verminderen dan wanneer insuline werd toegediend met een 
gewone pen. Net als bij de gezonde proefpersonen, vonden wij dat de insu-
line sneller werd opgenomen na  toediening met de jet injector dan met de 
gewone pen, al was dat in beide gevallen iets langzamer dan bij de gezonde 
vrijwilligers. De snellere insulineopname zorgde vervolgens voor een minder 
sterke glucosestijging na de testmaaltijd, met name in het eerste uur. 
Hierna onderzochten wij of toedienen van insuline met een jet injector zou 
kunnen helpen bij het zo snel mogelijk corrigeren van een sterk verhoogde 
bloedglucosespiegel. Een snelle correctie is belangrijk omdat de verhoogde 
bloedglucose op den duur kan leiden tot een levensgevaarlijke metabole 
ontregeling. Bovendien draagt een langdurig hoge glucosebelasting bij aan 
het verhoogde risico op schade aan de ogen, nieren en zenuwen. In het 
onderzoek dat wordt beschreven in hoofdstuk 7 vonden we dat verhoogde 
bloedglucosewaardes bij patiënten met diabetes inderdaad sneller waren te 
corrigeren als insuline met de jet injector werd toegediend in plaats van met 
de normale pen. Hierdoor werd de glucosebelasting verlaagd, met name 
tijdens de eerste twee uur van de test. Snellere daling van de bloedglucose-
spiegels zou de kans op een te lage bloedsuiker misschien kunnen verhogen, 
maar dat bleek niet het geval. De kans op hypoglykemieën bleek voor de 
beide apparaten even groot te zijn. Aangezien jet injectie de tijdsperiode 
met een te hoge bloedglucose verkortte, zou dit kunnen betekenen dat het 
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risico op ernstige metabole ontregelingen ook vermindert. Dit zou zowel 
in de thuissituatie als in een ziekenhuis nuttig kunnen zijn, aangezien een 
hyperglykemie regelmatig voorkomt bij patiënten die opgenomen zijn op 
een ziekenhuisafdeling.  
De huidige richtlijnen voor het herstellen van de hyperglykemie zijn vaak 
slecht gedefinieerd en maken geen gebruik van de individuele insuline-
gevoeligheid, die behoorlijk kan verschillen van patiënt tot patiënt. Het is 
daarom lastig om te schatten wat de juiste hoeveelheid insuline is die een 
patiënt nodig heeft om de bloedglucose weer te normaliseren. In de laat-
ste studie, beschreven in hoofdstuk 8, gebruikten we een algoritme om de 
juiste insulinedosis die nodig is om de bloedglucose te corrigeren zo goed 
mogelijk in te schatten. Tot onze verrassing bleek het algoritme redelijk 
nauwkeurig de juiste dosis te kunnen voorspellen, ondanks dat de formule 
aangaf dat hogere doses nodig waren dan vaak wordt aanbevolen. Ondanks 
de relatief hoge insulinedosis vonden we dat de initiële daling van de bloed-
glucose na het toedienen van insuline erg bescheiden was, slechts 3 mmol/l 
na een uur. Het duurde vaak meer dan 3 uur voordat de hyperglykemie was 
gecorrigeerd. Het is daarom aan te bevelen om een meting pas na twee uur 
te herhalen in plaats van na een uur, zoals vaak wordt aangeraden, omdat je 
dan beter in kan schatten of extra insuline nodig is om de gewenste daling 
te bereiken of dat kan worden afgewacht. 
In oudere onderzoeken wordt soms beschreven dat jet injectie blauwe 
plekken veroorzaakte. Tijdens onze experimenten zijn echter bij geen enkele 
deelnemer blauwe plekken ontstaan, ondanks de meer dan 200 toedienin-
gen met de jet injector. Deelnemers ervoeren de insulinetoediening met de 
jet injector als even (on)comfortabel als toediening met de normale pen. 
Het aantal deelnemers dat de voorkeur gaf aan jet injectie was gelijk aan 
het aantal deelnemers dat de voorkeur gaf aan toediening met de gewone 
pen. Het aantal patiënten dat glucose nodig had om een hypoglykemie te 
voorkomen tijdens de testen was in beide groepen eveneens gelijk. Er lijken 
dus geen verschillen te bestaan tussen de jet en de pen wat betreft de voor-
keur van deelnemers en de veiligheid van de apparaten. Wel moet worden 
vermeld dat er heel soms een zogenaamde “wet injection” optrad. Hierbij 
dringt de insuline niet door in de huid, maar blijft liggen op het huidopper-
vlak. Goede instructie en training zijn dus van het grootste belang voor het 
dagelijks gebruik van de jet injector. 
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Samenvattend tonen we in dit proefschrift aan dat jet injectie de subcutane 
opname van insuline bevordert. Dit leidt tot een sneller en korter gluco-
severlagend effect, bij zowel gezonde vrijwilligers als bij patiënten met 
diabetes en bij zowel snelwerkende als humane insuline. Dit voordeel was 
nog meer uitgesproken bij mensen met een hogere BMI. De jet injector lijkt 
daarbij niet te leiden tot meer variabiliteit in glucoseverlagend effect. 
Hoewel de jet injector dus duidelijke farmacologische voordelen heeft, zijn 
er ook beperkingen aan het apparaat. Het klaarmaken van de jet injector 
voor injectie duurt langer en is foutgevoeliger dan de gewone pen. Een 
vermindering van het aantal voorbereidende handelingen zou het apparaat 
gebruiksvriendelijker maken. Daarnaast kan het apparaat duurder zijn dan 
de conventionele pen. In Nederland wordt het apparaat overigens door alle 
verzekeringsmaatschappijen vergoed, maar in het buitenland is dat mogelijk 
anders. 
Aangezien de jet injector het glucosegehalte na de maaltijd beter reguleert 
dan de gewone pen, met name bij mensen met een hogere BMI, lijkt de 
jet injector vooral voordelig te zijn bij de behandeling van obese patiënten 
met diabetes, die last hebben van sterke glucosestijgingen na de maaltijd. 
Aangezien de jet injector bovendien gevaarlijk hoge bloedsuikers sneller 
corrigeert dan de gewone pen zou deze vorm van insulinetoediening ook 
een voordeel kunnen zijn op plekken waar ontregelingen vaak optreden. 
Hierbij valt te denken aan patiënten die zijn opgenomen in het ziekenhuis of 
zich presenteren op de spoedeisende hulp. 
Er blijft echter voldoende ruimte voor verder onderzoek. We weten bijvoor-
beeld niet of de betere glucosewaardes na de maaltijd ook leiden tot een 
betere gemiddelde glucosewaarde op de lange termijn, gemeten aan de 
hand van het HbA1c, of het risico op complicaties van diabetes daadwer-
kelijk verminderen. Toekomstig onderzoek moet zich daarom, ons inziens, 
richten op een lange termijnstudie, waarin patiënten dagelijks de jet injec-
tor gebruiken voor insulinetoediening. Daarnaast zou het interessant zijn 
om verschillende patiëntengroepen te testen, bijvoorbeeld obese patiënten 
met een hoge insulinebehoefte. 
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wandelen, ik heb goede hoop dat we het Pieterpad nog uitlopen voor ons 
pensioen! 
Lieve oud-Theresianen (en in het bijzonder Noor, Suus en Eef), dank voor 
alle creatieve hulp en ontspanning tijdens het onderzoek. Ik hoop dat we 
nog lang samen “ridders van de ronde tafel” zullen blijven. ‘On second 
thought, let’s not go to Camelot. It is a silly place.’
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beklimmen!
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